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Abstract: 
The Hippo pathway controls organ size and tumorigenesis by inhibiting cell 
proliferation and promoting apoptosis. KIBRA [kidney and brain expressed 
protein] is an upstream regulator of the Hippo-YAP signaling. The role KIBRA 
plays in mitosis has not been established. We show that KIBRA activates the 
Aurora kinases during mitosis and KIBRA promotes the phosphorylation of large 
tumor suppressor 2 by activating Aurora-A. We further show that knockdown of 
KIBRA causes mitotic abnormalities, including defects of spindle and centrosome 
formation and chromosome misalignment. The transcriptional co-activator with 
PDZ-binding motif is a downstream effector of the Hippo tumor suppressor 
pathway. In the current study, we define a new layer of regulation of TAZ activity 
that is critical for its oncogenic function. We found that TAZ is phosphorylated in 
vitro and in vivo by the mitotic kinase CDK1 at S90, S105, T326, and T346 during 
the G2/M phase of the cell cycle. Interestingly, the non-phosphorylatable mutant 
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possesses higher activity in epithelial-mesenchymal transition, anchorage-
independent growth, cell migration and invasion. Functional studies show that the 
non-phosphorylatable mutant of TAZ was sufficient to induce spindle and 
centrosome defects in immortalized epithelial cells. Together, our results reveal a 
previously unrecognized connection between TAZ oncogenicity and mitotic 
phospho-regulation. 
 
Recent studies have demonstrated that the Hippo signaling pathway plays a 
critical role in tumorigenesis. The functional significance of the main effector of 
the Hippo tumor suppressor pathway, YAP, in prostate cancer has remained 
elusive. We show that enhanced expression of YAP transformed immortalized 
prostate epithelial cells and promoted migration and invasion in both 
immortalized and cancerous prostate cells. YAP knockdown largely blocked cell 
division in LNCaP-C4-2 cells under androgen-deprivation conditions. In addition, 
ectopic expression of YAP was sufficient to promote LNCaP cells from androgen-
sensitive to androgen-insensitive in vitro and YAP conferred castration resistance 
in vivo. Our results identify YAP as a novel regulator in prostate cancer and as a 







TABLE OF CONTENTS 
Acknowlegements………………………………………………….………………….i 
Abstract………………………………………………………………………………...iv 
Table of contents…………………………………………………….………………..vi 
List of figures…………………………………………………………………………vii 
List of abbreviations……………………………………………….………………….x 
Chapter 1: Regulation and Functional Dissection of KIBRA and TAZ in 
Mitosis ………………………………………………………………..…………………1 
1.1 Introduction……………………………………………………….…………………2 




Chapter 2: Functional Study of Hippo-YAP Signaling in Prostate Cancer..73 
2.1 Introduction………………………………………………………………………...74 






List of Figures 
Figure 1.1 KIBRA activates Aurora kinases.  
Figure 1.2 KIBRA promotes phosphorylation of Lats2 on Ser83 through Aurora-A.  
Figure 1.3 Overexpression of Lats2 enhances mobility shift of KIBRA.  
Figure 1.4 Lats2 inhibits the phosphorylation of KIBRA on Ser539 via PP1.  
Figure 1.5 KIBRA knockdown causes mitotic defects in MCF-7 cells.  
Figure 1.6 KIBRA knockdown causes chromosome misalignment in HeLa cells.  
Figure 1.7 TAZ is phosphorylated by CDK1during G2/M arrest. 
Figure 1.8 TAZ is phosphorylated at multiple sites by CDK1 during nocodazole-
arrested G2/M phase. 
Figure 1.9 TAZ is phosphorylated at S90, S109, T326 and T346 during normal 
mitosis. 
Figure 1.10 Mitotic phosphorylation of TAZ inhibits EMT and anchorage-
independent growth. 
Figure 1.11 Mitotic phosphorylation of TAZ inhibits its oncogenic and 
transcriptional activity. 
Figure 1.12 Non-phosphorylatable TAZ induces mitotic defects in MCF10A cells. 
Figure 2.1 Upregulation of YAP in prostate tumors. 




Figure 2.3 YAP promotes cell proliferation and cellular transformation of RWPE-1 
cells.  
Figure 2.4 YAP promotes migration and invasion in RWPE-1 cells. 
Figure 2.5 YAP promotes migration and invasion in LNCaP cells. 
Figure 2.6 YAP promotes androgen-insensitive growth and Akt activation in 
LNCaP cells. 
Figure 2.7 YAP induces its targets and AR activation in LNCaP cells. 
Figure 2.8 YAP is upregulated in castration-resistant prostate cancer cells. 
Figure 2.9 YAP confers castration resistance in vivo. 
Figure 2.10 YAP knockdown in LNCaP-C4-2 cells impairs cell migration and 
invasion. 
Figure 2.11 YAP is required for castration-resistant growth of LNCaP-C4-2 cells. 
Figure 2.12 YAP partially blocks the AR targets induced by androgen analog. 
Figure 2.13 YAP is required for ERK-RSK activation upon androgen depletion in 
LNCaP-C4-2 cells. 
Figure 2.14 MEK-ERK inhibitor largely reduces migration and invasion ability of 
LNCaP-C4-2 cells under androgen-deprivation condition. 
Figure 2.15 A model for YAP signaling in castration-resistant prostate cancer. 
Figure 2.16 Generation of prostate-specific Tet-on inducible YAP-S127A mice. 
Figure 2.17 Doxycycline induces YAP expression and epithelial cell proliferation 
at early stage. 




Figure 2.19 Generation of prostate-specific deletion of MST1/2. 
Figure 2.20 MST1/2 specific deletion is not sufficient to promote tumorigenesis in 





List of Abbreviations 
ANKRD1: Ankyrin repeat domain-containing protein 1 
AR: androgen receptor 
CAMTA1: calmodulin-binding transcription activator 1 
CDK1: cyclin dependent kinase 1  
CRPC: castration-resistant prostate cancer 
CSS: charcoal-stripped serum 
CTGF: connective tissue growth factor 
Cyr61: Cysteine-rich angiogenic inducer 61 
DHT: dihydrotestosterone 
EMT: epithelial-to-mesenchymal transition  
ERK: extracellular signal-regulated kinases 
FBS: fetal bovine serum 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
GSK3: Glycogen synthase kinase 3 
GST: glutathione S-transferase  
HCC: hepatocellular carcinoma   
ITGB2: Integrin beta-2 
xi 
 
KIBRA: kidney and brain expressed protein 
KLK2: kallikrein-2 
Lats1/2: large tumor suppressor kinase 1/2  
MAPK: mitogen-activated protein kinases 
MEK: mitogen-activated protein kinase 
MOB1: Mps one binder 1 
Mst1/2: mammalian sterile-20 like 1/2 
NF2: neurofibromatosis type 2  
NKX3.1: NK3 homeobox 1 
NRK cells: normal rat kidney epithelial cells 
PB: probasin 
PGC-1: Peroxisome proliferator-activated receptor gamma coactivator 1  
PIN: prostatic intraepithelial neoplasia 
PLK1: polo-like kinase 1 
PP1: protein phosphatase 1 
PSA: prostate-specific antigen 
PTEN: phosphatase and tensin homolog 
RSK1/2: p90 ribosomal S6 kinase 1/2  
xii 
 
rtTA: reverse tetracycline-controlled transactivator 
TAZ: transcriptional coactivator with PDZ-binding motif 
TEAD1-4: TEA domain family member 1-4 
TGF: transforming growth factor 
TRAMP: transgenic adenocarcinoma of the prostate 
TRE: tetracycline response element 
WW45: protein salvador homolog 1, 45 kD WW domain protein  




















Regulation and Functional Dissection of KIBRA and TAZ in Mitosis  
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Mitosis is tightly controlled in order to achieve proper separation of chromosomes 
during cell division. Aberration in mitosis often causes genome instability or 
aneuploidy, a phenotype that many human malignant tumors exhibit. Various 
cellular surveillance mechanisms ensure the fidelity of cell cycle progression (1). 
The spindle assembly checkpoint ensures that mitosis proceeds accurately by 
arresting the cells in mitosis until all chromosomes are properly aligned at the 
metaphase plate (2). Defects in mitosis, such as chromosome misalignment or 
abnormal spindle formation, will therefore result in activation of the spindle 
assembly checkpoint and subsequent cell cycle arrest in metaphase. Thus, 
several antimitotic drugs have been developed, and they induce abnormal or 
prolonged cell cycle arrest in mitosis by perturbing microtubule dynamics, leading 
to mitotic catastrophe or cell death (3-5). 
 
The Hippo signaling pathway was originally discovered in Drosophila and plays 
an important role in tumorigenesis by regulating cell proliferation and apoptosis 
(6-8). In mammals, the core components of Hippo pathway form a kinase 
cascade comprising the tumor suppressors Mst1/2, WW45, Lats1/2 and Mob1. 
Protein kinases Mst1/2 form a complex with WW45 that phosphorylate and 
activate Lats1/2 as well as the adaptor protein Mob1. In turn, activated Lats1/2 
phosphorylates and inactivates the downstream effector YAP and its paralog 
TAZ. The phosphorylation of YAP at Serine 127 and TAZ at Serine 89 from the 
upstream Hippo pathway serve as 14-3-3-binding sites and sequesters YAP/TAZ 
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in the cytoplasm and further leads to protein degradation. Without the inhibition 
from the Hippo pathway, YAP and TAZ translocate into the nucleus, where they 
bind to transcription factors and induce transcription of genes that promote cell 
proliferation and inhibit apoptosis.  
 
Although many studies have demonstrated the important roles of the Hippo 
pathway in tumorigenesis, the underlying mechanisms remain unclear. Recent 
studies have shown that several key members of the Hippo pathway, such as 
Mst1/2, Lats1/2, WW45, and Mob1, are involved in regulating mitosis (9). 
Aberration of mitosis often causes genome instability/aneuploidy and subsequent 
oncogenesis. Thus, the Hippo pathway may contribute to tumorigenesis by 
regulating mitosis-related events. 
 
The WW domain-containing protein KIBRA (enriched in kidney and brain (10)) 
was recently identified as a novel regulator of the Hippo pathway in both 
Drosophila and mammalian cells (11-14).  In Drosophila, kibra was shown to 
function as a tumor suppressor that regulates the Hippo signaling pathway, which 
controls tissue growth and organ size (11-13). Kibra associates with Mer and Ex 
and directly binds to the Hippo–Sav complex to regulate the Hippo signaling 
pathway. Loss of kibra results in imaginal disc overgrowth, oogenesis defects 
and increased target gene expression of Hippo signaling (13). Human KIBRA 
was originally identified as a memory performance-associated protein in humans 
(15-19), and this function was recently confirmed in mice (20). The physiological 
function of KIBRA in non-neuronal cells is much less defined, although KIBRA 
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has been shown to be involved in cell migration in podocytes (21) and NRK cells 
(22)  and in epithelial cell polarity (23). KIBRA also interacts with the motor 
protein dynein light chain 1 to positively regulate cell growth in breast cancer 
cells (24). Interestingly, KIBRA expression is frequently down-regulated by 
promoter methylation in B-cell acute lymphocytic leukemia (25) and chronic 
lymphocytic leukemia (26) but not in epithelial cancers, including breast, 
colorectal, kidney, lung, and prostate, suggesting a potential cell type-specific 
tumor suppressive function of KIBRA. Recent studies demonstrated that KIBRA 
functions together with NF2 to stimulate phosphorylation of Lats1/2, thus 
inducing activation of the Hippo pathway to suppress the transcriptional activity of 
YAP, indicating that the tumor suppressive function of KIBRA may be conserved 
in the mammalian system. However, a role of KIBRA in development of cancer 
has not been established. 
 
Our group previously reported that KIBRA associates with Aurora-A (27) and 
Lats2 (14). Furthermore, we showed that KIBRA is phosphorylated by Aurora-A 
and -B kinases during mitosis (27). The functions of Aurora kinases and Lats2 in 
mitosis are well defined, but whether KIBRA has a mitotic role is currently 
unknown. It is largely unclear how KIBRA, Aurora, and Lats2 regulate each other 
within the KIBRA-Aurora-Lats2 axis. In this study, we show that KIBRA activates 
the Aurora kinases and stimulates the phosphorylation of Lats2 on Ser83 through 
activating Aurora-A. Lats2, in turn, inhibits Aurora-mediated phosphorylation of 
KIBRA. Importantly, knockdown of KIBRA causes mitotic defects. We propose 
5 
 
that KIBRA, in conjunction with Aurora-A and Lats2, is a novel mitotic component 
that regulates proper mitosis. 
 
TAZ (also called WWTR1-WW domain-containing transcription regulator protein 
1) is a transcriptional co-activator (28). TAZ is involved in human cancer and 
stem cell function (29-31). TAZ promotes tumor growth and metastasis in several 
types of cancers, including breast cancer (32-34), colon cancer (35-37), non-
small cell lung cancer (38-40) and glioblastoma (41). Correspondingly, TAZ 
expression/activity is upregulated in several human malignancies (29, 34, 42, 43) 
and the TAZ locus is amplified in some triple-negative breast cancers (33) and 
non-small cell lung cancer tumors (39). Recent studies showed that the TAZ 
gene is frequently fused with calmodulin-binding transcription activator 1 
(CAMTA1) in epithelioid hemangioendothelioma although the underlying 
mechanism of this fusion protein in cancer is still unclear (44, 45). TAZ also plays 
an important role in embryonic stem-cell self-renewal (46) and confers cancer 
stem cell-like properties in breast (33) and oral cancer cells (47). 
 
TAZ activity/function is regulated largely through the Hippo tumor suppressor 
pathway, which was originally discovered in Drosophila (48) and is highly 
conserved in mammals (7, 49, 50). The Hippo core kinases large tumor 
suppressor 1/2 (Lats1/2) phosphorylate and inactivate TAZ by sequestering it in 
the cytoplasm and promoting ubiquitination-dependent protein degradation (51, 
52). Many cues (e.g. the G-protein coupled receptor-Rho GTPase axis, 
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mechanical force and actin cytoskeleton etc.) regulate TAZ activity in a Hippo-
dependent manner (29, 31). Recent work has shown that other signals (e.g. 
GSK3 or Rho GTPase) can regulate TAZ in a Hippo-independent manner (53, 
54). TAZ also crosstalks with and is regulated by Wnt/β-catenin signaling. For 
example, TAZ, along with β-catenin, is degraded in the absence of Wnt signaling 
(8) and TAZ (and its paralog YAP) orchestrates the Wnt response by forming a 
complex with the β-catenin destruction complex (55). Furthermore, cytoplasmic 
TAZ (phosphorylated by Hippo) restricts β-catenin nuclear localization/activation 
directly (56) or through inhibiting Dishevelled phosphorylation (57). Besides the 
above regulation, however, it is not known whether and how TAZ is regulated 
during cell cycle progression/mitosis. 
 
We recently showed that some members of the Hippo pathway are 
phosphorylated by mitotic kinases Aurora and CDK1 during mitosis (27, 58). We 
and others found that TAZ was up shifted on a SDS-polyacrylamide gel (due to 
phosphorylation) during anti-microtubule drug-induced G2/M arrest (59, 60); 
however, the phosphorylation sites and the biological significance of this 
phosphorylation have remained elusive. In this study, we show that mitotic 
phosphorylation of TAZ on a number of sites occurs dynamically in cells in a 
CDK1-dependent manner. Interestingly, mitotic phosphorylation inactivates 
TAZ’s oncogenic activity. Therefore our data reveal a new layer of regulation for 




1.2 Materials and Methods 
Expression constructs 
We used the human full-length KIBRA cDNA (isoform 1) as a PCR template to 
clone KIBRA into the pcDNA3.1/FLAG (Invitrogen) vector or pcDNA3.1 
(Invitrogen) to generate N-terminal FLAG-tagged KIBRA. A human full-length 
Aurora-A cDNA clone (identification number 3051177, OpenBiosystems) was 
subcloned in-frame into the pEGFP-C1 vector (Clontech) to make the GFP-
Aurora-A construct. A human PP1c clone (identification number 3956353) was 
purchased from OpenBiosystems and subcloned into the pcDNA-HA vector. HA-
TAZ was a gift from Kun-Liang Guan (Addgene plasmid #32839) (47). To make 
the retroviral-mediated and GFP tagged TAZ expression constructs, the above 
cDNA was cloned into MaRXTMIV vector (14)  and pEGFP-C1 vector (Clontech), 
respectively. Deletion constructs were made by PCR and verified by sequencing 
and restriction enzyme digestion. Point mutations were generated by the Quik 
Change Site-Directed PCR mutagenesis kit (Stratagene) and verified by 
sequencing. 
 
Cell culture and transfection 
HEK293T, HeLa, and MCF-7 cell lines (purchased from American Type Culture 
Collection (ATCC), Manassas, VA) were maintained in Dulbecco's modified 
Eagle's medium containing 10% fetal bovine serum and antibiotics (Clontech 
Laboratories, Mountain View, CA). MCF-10A cells were cultured as described 
(34). The immortalized human pancreatic epithelial (HPNE) cells were cultured 
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as we previously described (34). Attractene (Qiagen) were used for transient 
overexpression transfections following the manufacturer’s instructions. Aurora-A 
siRNA (27) (SMART pool) and siRNA against Lats2 (SMART pool) were 
purchased from Dharmacon, Inc. (Lafayette, CO). PP1c siRNA (27) was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). SiRNA-1 and -2 
against KIBRA have been described previously (14). Nocodazole (100 ng/ml for 
16-20 h) and Taxol (0.1 µM for 16 h) were used to arrest cells in G2/M phase 
unless otherwise indicated. RO-3306 (CDK1 inhibitor) and roscovitine (CDKs 
inhibitor) were from ENZO Life Sciences. Purvalanol A (CDKs inhibitor) was 
purchased from Selleck. All other chemicals were either from Sigma or Thermo 
Fisher. 
Establishment of Tet-On-inducible Cell Lines  
The parental HeLa-rtTA cell line was purchased from Clontech Laboratories. We 
utilized the pRetroX-Tet-On advanced/pRetroX-Tight-Pur system (Clontech) to 
establish the cell lines expressing wild-type (WT) KIBRA or KIBRA S539A mutant 
(both are siRNA-resistant constructs). Cells were maintained in medium 
containing Tet system-approved fetal bovine serum (Clontech Laboratories). 
Cell Cycle Synchronization  
A double thymidine block was used as described previously with slight 
modification (61). Briefly, thymidine was added to subconfluent HeLa cells (2.5 
mm final), and the culture was incubated for 17 h. Cells were washed three times 
with PBS and allowed to recover with fresh medium for 10 h. The cells were then 
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incubated with 2.5 mm thymidine for another 18 h. The culture medium was 
replaced with fresh medium without the drug to release the cells from the block. 
Luciferase reporter assay 
Luciferase reporter assays were performed in 24-well platesin HEK293T cells. 
8XGTIIC-Luciferase (Addgene #34615, (62)), SV40-Renilla (Addgene 
#27163,(63)) and various TAZ mutants were co-transfected in triplicate as we 
have described previously (34). Luciferase activity was assayed at 48 hours post-
transfection by the Dual-luciferase reporter assay system (Promega) following 
the manufacturer’s instructions. 
 
Recombinant protein purification 
To make His-tagged human TAZ, full-length TAZ cDNA was subcloned into the 
pET-21c vector (Novagen/EMD Chemicals). The His-tagged proteins were 
bacterially expressed and purified on HisPurTM Cobalt spin columns (Pierce) 
following the manufacturer’s instructions. 
 
In vitro kinase assay 
About 1µg of His-TAZ was incubated with 100 ng recombinant CDK1/cyclin B 
complex (Signal Chem) or HeLa cell total lysates (treated with DMSO or Taxol) in 
kinase buffer (27) in the presence of 10 µCi γ-32P-ATP (3000 Ci/mmol, 
PerkinElmer). The samples were resolved by SDS-PAGE, transferred onto PVDF 
(Millipore) and visualized by autoradiography followed by Western blotting or 




Rabbit polyclonal and mouse monoclonal antibodies against human KIBRA have 
been described (27). The rabbit polyclonal phospho-specific antibody against 
KIBRA Ser539 has been described (27). Anti-FLAG, anti-HA, and anti-Myc 
antibodies were from Sigma. Anti-HA and anti-Myc antibodies from Santa Cruz 
Biotechnology were also used. Anti-β-actin, anti-cyclin B, anti-PP1c (pan), and 
anti-GFP antibodies were also from Santa Cruz Biotechnology. Mouse 
monoclonal anti-Aurora-A antibody was from Sigma. Anti-Lats2 was purchased 
from Bethyl Laboratories (Montgomery, TX). Rabbit polyclonal anti-α-tubulin and 
mouse monoclonal anti-γ-tubulin were from Abcam (Cambridge, MA). Anti-
phospho-Thr288 Aurora-A/Thr232 Aurora-B was from Cell Signaling Technology 
(Danvers, MA). Mouse monoclonal anti-phospho-Ser83 Lats2 (64) was obtained 
from Abnova (Taipei, Taiwan). The TAZ (V386) antibody from Cell Signaling 
Technology was used for Western blotting throughout the study. Rabbit 
polyclonal phospho-specific antibodies against TAZS90, S105, T326, and T346 
were generated and purified by AbMart. Anti-β-actin, anti-GFP, and anti-cyclin B 
antibodies were from Santa Cruz Biotechnology. Anti-glutathione S-transferase 
(GST) and anti-His antibodies were from Bethyl Laboratories. Anti-phospho-S10 
H3and anti-vimentin antibodies were from Cell Signaling Technology. Anti-E-
cadherin antibody was from BD Biosciences. Anti-β-tubulin (Sigma), anti-α-
tubulin (Abcam), and anti-γ-tubulin (Biolegend) antibodies were used for 




Immunoprecipitation, Western blot analysis and lambda phosphatase treatment 
For Immunoprecipitation, at 48 h after transfection, cells were lysed in 
radioimmune precipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF with 
protease inhibitor mixture (Roche Applied Science), and phosphatase inhibitors 
(10 mM pyrophosphate, 10 mM-glycerophosphate, 1.5 mM sodium 
orthovanadate, and 25 mM sodium fluoride). Proteins were immunoprecipitated 
with appropriate antibodies and Sepharose 4 Fast Flow Protein G beads (GE 
Healthcare). The proteins were separated on SDS polyacrylamide gels and 
transferred onto PVDF membranes (Millipore). HRP-conjugated anti-mouse or 
anti-rabbit IgG were from Pierce. ECL and SuperSignal West Pico 
Chemiluminescent substrate kits (Pierce) were used as HRP substrates. For 
lambda phosphatase treatment, Cells were lysed in Nonidet P-40 buffer (50 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, and 1% Nonidet P-40). The lysates were treated 
or not with 400 units ( 1 ul ) lamda phosphatase (P0753, NewEngland Biolabs) in 
the presence of 1 mM MnCl2 at 30°C for 30 min. A mixed solution of 10 mM 
sodium orthovanadate and 50 mM sodium fluoride was used as lamda 
phosphatase inhibitor. The reaction was stopped by the addition of SDS sample 
buffer followed by 5 min of heating at 95°C. 
 
Immunofluorescence staining 
Cells were fixed for 10 min with 100% methanol at −20°C, and then 
permeabilized with 1% Triton X-100 in PBS for 15 min at room temperature. 
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Nonspecific epitopes were blocked with 4% BSA in PBS for 1 h. After three 
washes with PBS (each for 10 min), cells were incubated with the primary 
antibodies diluted in 4% BSA in PBS for 2 h at room temperature or overnight at 
4 °C. Texas Red (GE Healthcare) and/or Alexa Fluor 594-conjugated (Molecular 
Probes, Eugene, OR) anti-rabbit/mouse IgG were incubated with the cells for 40 
min with 4% BSA in PBS at room temperature. After washing the cells three 
times (each wash for 10 min, with DAPI added in the final wash) with PBS, the 
stained cells were mounted with Fluoromount (Vector Laboratories, Burlingame, 
CA) and visualized with an upright, inverted, Axiovert 200 m Zeiss fluorescence 
microscope (Carl Zeiss, New York, NY). The Slidebook software (version 4.2, 
Intelligent Imaging Innovations, Denver, CO) was used for analyzing and 
processing all immunofluorescence images. For phenotypic analysis, we 
independently analyzed and scored the mitotic defects in each experiment. For 
peptide blocking, a protocol from Abcam website was used and as we previously 
described (59). 
 
Soft agar assay, cell migration, and invasion assays 
Soft agar assays were conducted in 6-well plates. The base layer of each well 
consisted of 1.5ml with final concentrations of 1 x media and 1% agarose. Plates 
were chilled at room temperature until solid, at which point a 2 ml growth medium 
with 0.5% agarose layer was poured, consisting of cells suspended (MCF10A 
cells: 5000 cells per well, HPNE cells: 1X104 cells per well). Plates were again 
chilled at room temperature until the growth layer congealed. A further 1 ml of 1x 
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culture media without agarose was added on top of the growth layer. The growth 
medium was changed every week for 3-4 weeks, after which colonies were fixed 
with 3.7% PFA and stained with 0.005% crystal violet for 1 minute followed by 
PBS wash for 3 times of 5 minutes each. Data were obtained from three 
independent experiments. 
 
In vitro analysis of invasion and migration was assessed using the BioCoat 
invasion system (BD Biosciences) and Transwell system (Corning), respectively, 
according to the manufacturer's instructions. The cells were trypsinized and 
resuspended in the medium without serum and/or growth factor at the indicated 
concentration (MCF10A: 1.0X105/well, HPNE 1.0X105/well for migration assay; 
MCF10A: 5.0X104/well, HPNE: 5.0X104/well for invasion assay). 600 µl of basal 
medium with 10%FBS was added to the bottom of the migration assay chamber, 
and 750 µl for BioCoat invasion chamber. The insert was carefully placed into 
each well to avoid leaving a bubble between insert and the medium in the bottom 
chamber. 100 µl or 500 µl of the above mentioned cell suspension was added to 
the insert for migration and invasion assay, respectively. After the incubation at 
37°C for 18 to 24 hours, the plate was removed from the incubator. The cells 
were fixed with 3.7% PFA and the cells inside the inserts were removed with 
cotton swabs. Then, the invasive and migratory cells were stained with ProLong® 
Gold Antifade Reagent with DAPI. The relative invading and migrating rate were 
calculated by the number of cells invading and migrating through the membrane, 




Statistical significance was performed using a two-tailed, unpaired Student’s t-




















1.3.1 KIBRA Regulates Aurora Kinase Activity and Is Required for Precise 
Chromosome Alignment During Mitosis. 
1.3.1.1 KIBRA activates Aurora kinases and is required for Aurora 
activation during mitosis 
We previously identified Ser539 of KIBRA as a major phosphorylation site for 
Aurora kinases in mitosis (27). As many Aurora substrates also function as 
activators of the kinase, we tested whether this is also the case for KIBRA. To 
this end, we examined Aurora kinase activity by using the phospho-specific 
antibody against the autophosphorylation sites (Thr288 for Aurora-A, Thr232 for 
Aurora-B, and Thr198 for Aurora-C). As shown in Fig. 1.1A, overexpression of 
KIBRA strongly stimulated Aurora-A kinase activation, as indicated by an 
increase of phosphorylation of Aurora-A on Thr288. As expected, the 
phosphorylation of Thr288 of Aurora-A-KD (kinase dead/inactive) form was not 
increased by KIBRA. Interestingly, KIBRA S539A, a mutant that is not 
phosphorylated by Aurora-A, also promoted the phosphorylation of Aurora-A on 
Thr288 and did so as well as wild-type KIBRA, suggesting that Aurora-mediated 
phosphorylation is not required for KIBRA to activate Aurora-A. Similarly, 
overexpression of KIBRA enhanced the phosphorylation of Aurora-B on Thr232 
(Fig. 1.1B). We noticed that there was still some phosphorylation of Thr232 when 
Aurora-B KD was used (Fig. 1.1B, lanes 4–6), suggesting the existence of 
another kinase that phosphorylated Aurora-B on Thr232. 
16 
 
The expression of Aurora-A is diminished in interphase cells, whereas Aurora-A 
is stabilized and activated by phosphorylation during mitosis (61). To further 
explore the involvement of KIBRA in the activation of Aurora kinase, we 
established doxycycline-inducible HeLa cells expressing siRNA-resistant KIBRA 
or KIBRA S539A and employed a double thymidine block to synchronize these 
cells in mitosis (Fig. 1.1C). As shown in Fig. 1.1D, Aurora kinases were clearly 
activated in control cells (revealed by an increase of phosphorylation of Aurora-A 
Thr288 and Aurora-B Thr232) 14 h after being released from the double 
thymidine block (compare lane 3 with lane 1). However, activation of Aurora 
kinases is largely diminished in KIBRA knockdown cells at the same time point, 
indicating that KIBRA is required for full activation of Aurora kinases when cells 
enter mitosis (Fig. 1.1D, compare lane 6 with lane 3). Aurora-A and cyclin B 
levels are increased similarly in both control and KIBRA knockdown cells when 
the cells are released into mitosis, suggesting that KIBRA knockdown did not 
affect the overall entry into mitosis at the time points examined. Importantly, the 
defect caused by KIBRA knockdown was completely rescued by re-expression of 
either siRNA-resistant wild-type KIBRA or KIBRA S539A, further confirming that 
Aurora-mediated phosphorylation is not required for KIBRA to promote activation 
of Aurora (Fig. 1.1D, compare lanes 9 and 12 with lane 6). Taken together, the 







Figure 1.1 KIBRA activates Aurora kinases.  
A, various plasmids were transfected into HEK293T cells as indicated. At 48 h 
after transfection, cells were lysed, and proteins were separated by SDS-PAGE 
and transferred onto PVDF membranes, followed by Western blot analysis with 
the indicated antibodies. In all of the figures, M(K) indicates positions where the 
relevant molecular markers migrated.  
B, transfection and Western blotting were done as described in A.  
C, schematic diagram for D. Double thymidine block was employed as described 
under “Materials and Methods.” siRNA transfection and doxycycline (DOX) 
addition were done after the first thymidine block.  
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D, the doxycycline-inducible HeLa cell lines expressing siRNA-resistant (siRes) 
wild-type KIBRA or KIBRA S539A were established, and the cells were treated 
as described in C. The samples were probed with the indicated antibodies. DT, 
double thymidine block. The asterisk marks the incompletely stripped actin. 
Doxycycline (Sigma) was used at 50–100 ng/ml to induce exogenous siRNA-














1.3.1.2 KIBRA promotes phosphorylation of Lats2 on Ser83 through 
Aurora-A  
Ser83 of Lats2 was shown to be phosphorylated during mitosis by Aurora-A (64). 
We recently reported that KIBRA associates with both Lats2 (14) and Aurora-A 
(27). These findings, along with the data from Fig. 1.1, led us to determine 
whether KIBRA is involved in controlling phosphorylation of Ser83 on Lats2. 
Figure 1.2A shows that enhanced expression of either KIBRA or KIBRA S539A 
similarly promoted the phosphorylation of Lats2 on Ser83. However, deletion of 
the WW domains (which abolishes the interaction between KIBRA and Lats2(14)) 
did not affect the ability of KIBRA to stimulate the phosphorylation on Ser83 of 
Lats2. At this point, we reasoned that KIBRA promotes the phosphorylation of 
Lats2 on Ser83 by activating Aurora-A kinase. To test this hypothesis, we 
introduced Aurora-A-KD (kinase dead/inactive) or Aurora-A siRNA to determine 
the role of Aurora-A in mediating the KIBRA-dependent phosphorylation of Lats2 
on Ser83. As shown in Fig. 1.2, B and C, overexpression of Aurora-A-KD or 
knocking down Aurora-A greatly impaired the phosphorylation of Ser83 on Lats2 
induced by KIBRA, suggesting that KIBRA promotes Ser83 phosphorylation of 
Lats2 by activating Aurora-A kinase and that the Aurora-A-KD form has a 
dominant-negative function. Interestingly, although Aurora-A robustly 
phosphorylated Lats2 on Ser83 (Fig. 1.2B, lane 3), overexpression of Aurora-B 
did not increase the phosphorylation of Lats2 on Ser83 and expression of 
Aurora-B-KD had no effect on the ability of KIBRA to promote Ser83 
phosphorylation of Lats2 (Fig. 1.2D).  
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Because KIBRA, Aurora-A, and Lats2 associate with each other and Aurora-A is 
required for KIBRA to promote Lats2 phosphorylation, we further explored 
whether the interaction between KIBRA and Lats2 is Aurora-A-dependent. 
Surprisingly, neither overexpression of Aurora-A nor Aurora-A knockdown 
affected the association between KIBRA and Lats2 (Fig. 1.2E). In addition, 
neither knockdown nor enhanced expression of KIBRA affected the interaction 
between Lats2 and Aurora-A (Fig. 1.2F). These data suggest that KIBRA, 







Figure 1.2 KIBRA promotes phosphorylation of Lats2 on Ser83 through 
Aurora-A.  
A, Myc-tagged Lats2 was transfected into HEK293T cells with FLAG-tagged 
KIBRA or KIBRA mutants as indicated. At 48 h after transfection, cells were lysed, 
and proteins were immunoprecipitated with Myc antibody followed by Western 
blot analysis with the indicated antibodies. Lysates were also probed with FLAG 
antibody to check the expression of transfected KIBRA.  
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B, HEK293T cells were transiently transfected with plasmids as indicated. At 48 h 
after transfection, Myc-Lats2 was immunoprecipitated and probed with p-Lats2 
Ser83 and Myc antibodies. Lysates without immunoprecipitation were also 
probed with FLAG and GFP antibodies to check the expression of KIBRA and 
Aurora-A (Aur-A).  
C, HEK293T cells were transiently transfected with control siRNA (lanes 1 and 2) 
or siRNA against Aurora-A (lane 3) and plasmids as indicated. 
Immunoprecipitation and Western blotting were done as described in B.  
D, transfection, immunoprecipitation, and Western blot analysis were performed 
as described in B except GFP-Aurora-B and GFP-Aurora-B-KD were used.  
E, HEK293T cells were transiently transfected with control siRNA (lanes 1–3) or 
siRNA against Aurora-A (lane 4) and plasmids as indicated. At 48 h post-
transfection, cells were lysed and immunoprecipitated with FLAG antibody. The 
immunoprecipitates were probed with the indicated antibodies. Total cell lysates 
were used to check the expression of Aurora-A and Myc-Lats2.  
F, HEK293T cells were transiently transfected with control siRNA (lanes 1–3) or 
siRNA targeting KIBRA and various plasmids as indicated. Cells were harvested 
at 48 h post-transfection. The immunoprecipitates and total cell lysates without 
immunoprecipitation were probed with the indicated antibodies. HC, IgG heavy 
chain. M(K) indicates positions where the relevant molecular markers migrated. 
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1.3.1.3 Lats2 overexpression enhances KIBRA mobility  
During our experiments, we noticed the migration of KIBRA increased on SDS 
gels when Lats2 was overexpressed ((14); Fig. 1.3A, compare lane 2 with lane 1). 
The kinase activity and Aurora-A-mediated phosphorylation on Ser83 were not 
required for this function of Lats2 (Fig. 1.3A, compare lanes 2–4 with lane 1). 
Interestingly, Lats2, but not Mst1 or its close homolog Lats1, possessed this 
function (Fig. 1.3A, compare lanes 5 and 6 with lanes 2–4), confirming the 
specificity. To further explore which domain/region is required for Lats2 to 
enhance the mobility of KIBRA, we generated a series of truncated Lats2 
constructs (Fig. 1.3B). Deletion of the C-terminal 400 amino acids did not 
significantly alter the ability of Lats2 to enhance the mobility of KIBRA (Fig. 1.3C). 
However, deletion of an additional 100 amino acids abolished the ability of Lats2 
to increase the mobility of KIBRA, suggesting that the region encompassing 
amino acids 588–689 is required for Lats2 to perform this function. Additional 
truncated constructs were made with deletions within this region, and our data 
suggest that the highly conserved region (amino acids 598–619 of human Lats2, 
Fig. 1.3B) is required for Lats2 to enhance the mobility of KIBRA (Fig. 1.3D). 
Internal deletion of these 22 amino acids in Lats2 (Lats2Δ22) largely abolished its 






Figure 1.3 Overexpression of Lats2 enhances mobility shift of KIBRA.  
A, HA-tagged KIBRA was transfected into HEK293T cells with empty vector or 
various DNAs as indicated. At 48 h post-transfection, total cell lysates were 
probed with the indicated antibodies.  
B, schematic diagram of various Lats2 constructs used for C--E.  
C–E, FLAG-tagged KIBRA was transfected into HEK293T cells with empty vector 
or plasmids as indicated. At 48 h post-transfection, total cell lysates were probed 
with the indicated antibodies. M(K) indicates positions where the relevant 
molecular markers migrated. 
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1.3.1.4 Lats2 inhibits phosphorylation of KIBRA on Ser539  
We previously reported that during mitosis Ser539 of KIBRA is phosphorylated 
by Aurora kinases and that KIBRA migrates differently on SDS-polyacrylamide 
gels depending on its phosphorylation status (27). Thus, we tested whether 
expression of Lats2 might inhibit the phosphorylation of KIBRA using phospho-
specific antibodies. Overexpression of Lats2, but not Lats2Δ22, strongly 
decreased the phosphorylation of KIBRA on Ser539 (Fig. 1.4A). In addition, 
knockdown of Lats2 increased the phosphorylation of transfected KIBRA on 
Ser539 (Fig. 1.4B). Taken together, these data suggest that during mitosis Lats2 
antagonizes Aurora-mediated phosphorylation of KIBRA on Ser539. 
We recently reported that PP1 can dephosphorylate Ser539 of KIBRA (27). Thus, 
we explored whether PP1 is required for the Lats2-dependent reduction of 
phosphorylation of KIBRA Ser539. As shown in Fig. 1.4C, in the presence of 
siRNA against PP1c (catalytic subunit), Lats2 inhibited the phosphorylation of 
KIBRA on Ser539 less efficiently (compare lane 3 with lane 2), indicating that 









Figure 1.4 Lats2 inhibits the phosphorylation of KIBRA on Ser539 via PP1.  
A, HEK293T cells were transfected with FLAG-KIBRA and plasmids as indicated. 
At 48 h post-transfection, the cells were lysed and immunoprecipitated with 
FLAG antibody. The immunoprecipitates were probed with anti-phospho-Ser539 
KIBRA and subsequent anti-FLAG antibodies.  
B, HeLa cells were transfected with FLAG-KIBRA and control siRNA (lane 1) or 
siRNA against Lats2 (lane 2) for 48 h. FLAG-KIBRA was immunoprecipitated and 
probed with the indicated antibodies. Total cell lysates without 
immunoprecipitation were also analyzed.  
C, HeLa cells were transfected with control siRNA (lanes 1 and 2) or siRNA 
targeting PP1 (lane 3) and plasmids as indicated. FLAG-KIBRA was 
immunoprecipitated and probed with phospho-KIBRA Ser539 and subsequent 
anti-FLAG antibodies. Total cell lysates without immunoprecipitation were also 




1.3.1.5 KIBRA knockdown causes mitotic defects  
We found that KIBRA activates the important mitotic kinase, Aurora-A (Fig. 1.1). 
Moreover, KIBRA is a verified substrate of both Aurora- A and -B. Therefore, we 
expected KIBRA to play an important role in the process of mitosis. To test the 
function of KIBRA in mitosis, we knocked down KIBRA in both MCF-7 and HeLa 
cells using two different siRNA oligonucleotides. As seen in Fig. 1.5A, 48 h after 
transfection, both oligonucleotides efficiently depleted KIBRA in HeLa as well as 
MCF-7 cells. We first depleted KIBRA in MCF-7 cells and used 
immunofluorescence to identify any mitotic defects. The depletion of KIBRA in 
MCF-7 cells caused striking defects in spindle assembly (Fig. 1.5B and C) as 
well as the centrosome number (Fig. 1.5B and D). KIBRA activates Aurora-A and 
Aurora-A activity is known to be required for proper spindle assembly and 
centrosome function. Hence, it is likely for these reasons that depleting KIBRA 
caused defects in spindle assembly and centrosome number. We observed that 
the knockdown of KIBRA strongly affected the spindle structure (Fig. 1.5B). The 
spindle microtubules were abnormally organized in KIBRA siRNA cells (Fig. 1.5B, 
middle panels). Furthermore, the centrosomes appeared fragmented (Fig. 1.5B, 
lowest panels). About 48% of the cells that were transfected with KIBRA siRNA-1 
and 35% of the cells that were transfected with KIBRA siRNA-2 displayed 
abnormally assembled metaphase spindles (Fig. 1.5C). Furthermore, 38% of the 
cells that were transfected with KIBRA siRNA-1 and >33% of the cells that were 
transfected with KIBRA siRNA-2 exhibited defects in centrosome numbers (Fig. 
1.5D). These data show that KIBRA plays a crucial role in mitosis by regulating 
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centrosome function and spindle assembly, possibly via regulating Aurora-A 
activity. 
Because we detected abnormal spindles in KIBRA siRNA MCF-7 cells, we 
expected that the knockdown of KIBRA would also impair chromosome 
alignment during mitosis. To test this hypothesis, HeLa cells were transfected 
with either a scrambled, non-targeting siRNA or with siRNA against KIBRA. 
Furthermore, these cells were either treated with dimethyl sulfoxide (control) or 
with monastrol (an Eg5 inhibitor that arrests cells in mitosis). The monastrol was 
then washed out, and the cells were allowed to proceed normally through mitosis 
(65, 66). All cells were then subjected to immunofluorescence analysis to 
visualize abnormalities in chromosome alignment. Remarkably, the depletion of 
KIBRA from HeLa cells caused the appearance of lagging chromosomes (Fig. 
1.6A, panel iv), chromosome bridges (Fig. 1.6A, panel v), and micronuclei (Fig. 
1.6A, panel vi) during different stages of mitosis. Additionally, we observed that 
the knockdown of KIBRA by another siRNA in HeLa cells also yielded abnormal 
metaphase chromosome alignment (Fig. 1.6B). In addition, we observed that the 
enrichment of mitotic cells by monastrol treatment further increased the 
percentage of cells with lagging chromosomes that were obtained upon 
knockdown of KIBRA (Fig. 1.6C). All these data establish a very important role 






Figure 1.5 KIBRA knockdown causes mitotic defects in MCF-7 cells.  
A, MCF-7 and HeLa cells were treated with control siRNA (20 nm, lanes 1 and 4) 
and siRNA targeting KIBRA (20 nm, lanes 2, 3, 5, and 6) for 48 h, and 
knockdown efficiency was analyzed by Western blotting.  
B, MCF-7 cells were transfected with KIBRA siRNA. At 24–48 h post-transfection, 
cells were fixed, permeabilized, and stained (see “Experimental Procedures”) 
with antibodies as indicated. Representative confocal images are shown. Scale 
bar, 10 μm.  
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C, quantification of spindle defects in KIBRA knockdown cells. The graph 
represents the percentage of cells from three independent experiments, and at 
least 150 mitotic cells were counted in each group. Error bars represent S.E. **, p 
< 0.01; *, p < 0.05(t test).  
D, quantification of centrosome defects in KIBRA knockdown cells. The graph 
represents the percentage of cells from three independent experiments, and at 
least 150 mitotic cells were counted in each group. Error bars represent S.E. **, p 



















Figure 1.6 KIBRA knockdown causes chromosome misalignment in HeLa 
cells.  
A and B, HeLa cells were transfected with the siRNA oligonucleotides as 
indicated (20 nm). At 48 h post-transfection, cells were treated with monastrol (an 
Eg5 inhibitor that arrests cells in mitosis) for 2 h. The monastrol was then washed 
out, and the cells were allowed to proceed normally through mitosis (65, 66). 
These cells were then fixed and stained with α-tubulin antibody. DAPI was used 
to visualize the DNA. Cells at various mitotic phases are shown. Yellow arrows 
mark the abnormalities in KIBRA knockdown cells. Scale bar, 10 μm.  
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C, Quantification of chromosome misalignment (lagging chromosome) in KIBRA 
knockdown cells. The graph represents the percentage of cells from three 
independent experiments, and at least 150 mitotic cells were counted in each 






















1.3.2 CDK1 Phosphorylation of TAZ in Mitosis Inhibits its Oncogenic 
Activity. 
1.3.2.1 TAZ is phosphorylated during anti-mitotic drug-inducedG2/M arrest 
We and others showed that TAZ protein is upshifted on SDS-polyacrylamide gels 
during Taxol or nocodazole (both agents arrest cells in G2/M) -induced mitotic 
arrest (59, 60). As shown in Figure 7A, the dramatic mobility up-shift of TAZ was 
readily detected by a phos-tag gel (Fig. 1.7A).Lambda phosphatase treatment 
converted all slow-migrating bands to fast-migrating bands, confirming that the 
mobility shift of TAZ during G2/M is caused by phosphorylation (Fig. 1.7B). Since 
TAZ is a paralog of YAP and mitotic phosphorylation of YAP is mediated by the 
mitotic kinase CDK1, we tested whether CDK1 is also responsible for TAZ 
phosphorylation. As shown in Figure 7C, both RO3306 (a CDK1 inhibitor) and 
Purvalanol A (an inhibitor for CDK1 and other CDKs) completely reverted the 
mobility shift of TAZ, suggesting that CDK1 is likely to be responsible for TAZ 
phosphorylation. Inhibition of other mitotic kinases Aurora-A, B, C (with VX-680) 
and PLK1 (with BI2536) did not alter the TAZ phosphorylation (data not shown). 
 
1.3.2.2 CDK1 phosphorylates TAZ in vitro 
Next, we determined whether CDK1 kinase can directly phosphorylate TAZ in 
vitro with His-tagged TAZ as substrates. Figure 1.7D shows that Taxol-treated 
mitotic lysates robustly phosphorylated TAZ and that CDK1 inhibitors greatly 
reduced phosphorylation of His-TAZ (Fig. 1.7D). Furthermore, purified 
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CDK1/cyclin B complex phosphorylated His-TAZ in vitro (Fig. 1.7E). These 
results indicate that CDK1 phosphorylated TAZ in vitro. 
 
There are a total of six sites that fit the proline-directed consensus sequence of 
CDK1-phosphorylation sites(67). Two of them (threonine 175 and threonine 285) 
do not exist in mouse and rat and are excluded for further study. Interestingly, the 
remaining four sites (serine 90, serine 105, threonine 326, and threonine 346) 
have been identified as mitotic phosphorylation sites from large scale proteomic 
studies(68).  Mutating these four sites to non-phosphorylatable alanines (TAZ-
4A) almost completely abolished the 32P incorporation into TAZ, suggesting that 
S90, S105, T326 and T346 are the main CDK1 phosphorylation sites (Fig. 1.7F). 
Metabolic labeling confirmed that wild type TAZ was phosphorylated during 
Taxol-treatment and TAZ-4A was not able to be further phosphorylated during 
Taxol-induced G2/M arrest (Fig. 1.7G), indicating that these four sites are the 
main phosphorylation sites during G2/M in cells. 
 
1.3.2.3 CDK1/cyclin B complex phosphorylates TAZ at S90 and S105 in vitro 
We have generated phospho-specific antibodies against S90, S105, T326, and 
T346. Using these antibodies we demonstrated that CDK1 phosphorylated TAZ 
atS90 and S105 in vitro (Fig. 1.7H,I). Addition of RO3306 abolished the 
phosphorylation (Fig. 1.7H,I). We could not detect a signal when anti-p-TAZ T326 









Figure 1.7 TAZ is phosphorylated by CDK1 during G2/M arrest. 
A, HeLa cells were treated with DMSO (control), Taxol (0.1 µM for 16 h) or 
Nocodazole (Noco, 100 ng/ml for 16 h). Total cell lysates were probed with the 
indicated antibodies. O marks the non-phosphorylated TAZ; * and ** mark the 
phosphorylated TAZ. 
B, HeLa cells were treated with Nocodazole (Noco) as indicated and cell lysates 
were further treated with (+) or without (-) λ phosphatase (ppase). Total cell 
lysates were probed with anti-TAZ antibody. 
C, HeLa cells were treated with Nocodazole (Noco). RO3306 (CDK1 inhibitor) or 
Purvalanol A (CDKs inhibitor) were added (with or without MG132) into the cells 
2 h before harvesting the cells. Proteasome inhibitor MG132 was also added 
(together with inhibitors) to prevent cyclin B from degradation and cells from 
exiting from mitosis.Total cell lysates were subjected to Western blotting with the 
indicated antibodies. 
D, In vitro kinase assays using HeLa cell lysates to phosphorylate recombinant 
His-TAZ in the presence of 32P. Asy: asynchronized; Tax: Taxol-treated.The 
samples were also probed with cyclin B and β-actin antibodies. 
E, In vitro kinase assays with purified CDK1/cyclin B complex. RO3306 (5 µM) or 
Purvalanol (10 µM) was used to inhibit CDK1 kinase activity. 
F, In vitro kinase assays with purified CDK1/cyclin B complexto phosphorylate 
recombinant His-TAZ or His-TAZ-4A.  
G, GFP-tagged TAZ or –TAZ-4A were transfected into HeLa cells. At 24 h post-
transfection, cells were treated with nocodazole (Noco) for 16 h and metabolically 
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labeled in the presence of 32P for an additional 2 h as we previously 
described(58). 
H,I, In vitro kinase assays were done as in E except anti-phospho-TAZS90 and 
S105 antibodies were used. 
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1.3.2.4 Phosphorylation of TAZ occurs in cells during normal mitosis 
Next, we performed immunofluorescence microscopy with these phospho-
specific antibodies. Strong and specific signals were detected in nocodazole-
arrested prometaphase cells for all antibodies against S90, S105, T326, and 
T346 (Fig. 1.8A-D, top panels, red arrows). Very weak or no signal was detected 
in interphase cells (Fig. 1.8A-D, yellow arrows). Importantly, phosphopeptide-, 
but not non-phosphopeptide- (control peptide), incubation largely blocked the 
signal, suggesting that these antibodies specifically recognize phosphorylated 
TAZ (Fig. 1.8A-D, middle panels). Addition of RO3306 largely abolished the 
signals detected by p-TAZS90, S105, T326, and T346 antibodies in 
prometaphase cells, further indicating that the phosphorylation is CDK1 
dependent (Fig. 1.8A-D, low panels). 
 
To further investigate the dynamics of TAZ phosphorylation in cells during 
unperturbed/normal mitosis, we utilized double thymidine block and release and 
determined the phospho-status of TAZ during different cell-cycle phases. We 
found that the p-TAZS90 signal was readily detectable in prophase and peaked 
in prometaphase/metaphase. The signal was then weakened in anaphase and 
further diminished in telophase and cytokinesis (Fig. 1.9A). We observed similar 
staining patterns when the p-TAZ S105, T326, and T346 antibodies were used 
for staining (Fig. 1.9B,C and data not shown). These data strongly indicate that 









Figure 1.8 TAZ is phosphorylated at multiple sites by CDK1 during 
nocodazole-arrested G2/M phase. 
A, HeLa cells were treated with nocodazole for overnight and fixed. The cells 
were then incubated with or without peptides used for immunonizing rabbits prior 
to phospho-TAZ S90 staining. CDK1 inhibitor (RO3306) was added 2 h before 
the cells were fixed (bottom low). 
B-D, Similar experiments were done as in A with different phospho-specific 
antibodies. Red and yellow arrows mark some of the prometaphase cells and the 









A,B, HeLa cells were synchronized by a double thymidine (DT) block and release 
method. Cells were stained with p-TAZ S90 (A) and p-TAZS105 (B).Cells were 
co-stained with DAPI and β-tubulin to indicate the various phases. 
C, HeLa cells were synchronized as in (A) and stained with DAPI, phospho-
specific antibodies against TAZ, and β-tubulin. A lower power (40X) objective 
lens was used for photography to view various phases of the cells in a field. Red 
and yellow arrows in (C) mark the mitotic and interphase cells, respectively. 
43 
 
1.3.2.5 Mitotic phosphorylation inhibits TAZ in EMT and cellular 
transformation 
We next examined the biological significance of mitotic phosphorylation of TAZ. 
Overexpression of TAZ promotes epithelial-mesenchymal transition (EMT) and 
transforms MCF10A cells (51, 69). We first established pooled cell lines stably 
expressing TAZ or TAZ mutants (Fig. 1.10A). We confirmed that the epithelial 
marker E-cadherin was downregulated and vimentin (a mesenchymal marker) 
was greatly upregulated in cells expressing active TAZ (TAZ-S89A) (Fig. 1.10A). 
Interestingly, TAZ-4A (non-mitotic phosphorylatable mutant) possesses 
higheractivity in regulating EMT in MCF10A cells when compared to wild type 
TAZ (Fig. 1.10A,B). In contrast, ectopic expression of TAZ-4D (a mitotic 
phosphomimetic mutant) failed to alter EMT in MCF10A cells (Fig. 1.10A,B). 
Mutating phosphorylation sites to alanines (TAZ-S89A/4A) further increased 
TAZ-S89A activity in promoting EMT (Fig. 1.10A,B), suggesting that mitotic 
phosphorylation inhibits TAZ in EMT. Consistent with the EMT results, we 
observed significant morphology change of MCF10A cells expressing TAZ-4A, 
but not vector, wild type TAZ or TAZ-4D (Fig. 1.10C). Again, the most significant 
change was observed in TAZ-S89A/4A-expressing cells (Fig. 1.10A-C).  
 
MCF10A cells expressing TAZ-S89A/4A formed colonies in soft agar, however, 
all other cells failed to produce any obvious colonies when fewer cells were 
seeded (Fig. 1.10D). Again, TAZ-S89A/4Apossesses higher activity compared to 
TAZ-S89A in stimulating anchorage-independent growth in soft agar (Fig. 
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1.10E,F). TAZ, TAZ-4A or TAZ-4D overexpression failed to produce colonies in 
soft agar even when 10,000 cells were seeded (data not shown). Similarly, only 
TAZ-S89A/4A-expressing HPNE (an immortalized pancreatic epithelial cell line) 
cells were able to produce colonies in soft agar (Fig. 1.10G-I). Together, these 
data strongly suggest that mitotic phosphorylation inhibits TAZ-mediated cellular 








Figure 1.10 Mitotic phosphorylation of TAZ inhibits EMT and anchorage-
independent growth. 
A, Establishment of MCF10A cells stably express vector, TAZ, TAZ-S89A, TAZ-
4A, TAZ-4D, and TAZ-S89A/4A (TAZ-5A).4A: S90A/S105A/T326A/T346A; 5A: 
S89A/4A; 4D: S90D/S105D/T326D/T346D. The total cell lysates were probed 
with the indicated antibodies. 
B, Immunofluorescence staining with E-cadherin inMCF10A cells established in 
A. 
C, Morphology change of MCF10A cells expressing vector or various TAZ 
mutants. 
D-F, Colony assays in soft agar (anchorage-independent growth) in MCF10A 
cells established in A. 
G, Establishment of HPNE cells stably express vector, TAZ-S89A, TAZ-5A 
(S89A/4A). 












1.3.2.6 Mitotic phosphorylation of TAZ impairs cell motility and 
transcriptional activity 
Several studies showed that TAZ/TAZ-S89A also promotes cell migration, 
invasion and metastasis in animal (70, 71). We therefore tested whether mitotic 
phosphorylation affects TAZ’s activity in cell motility. As expected, ectopic 
expression of TAZ or TAZ-S89A increased migration of MCF10A cells assayed 
by wound healing (Fig. 1.11A). Mutating CDK1-mediated phosphorylation sites to 
alanines (TAZ-4A) increased migration to a greater extent when compared to 
wildtype TAZ (Fig. 1.11A). In contrast, cells expressingTAZ-4D possess much 
lower migratory activity than cells expressing wild type TAZ (Fig. 1.11A). Cells 
expressing TAZ-S89A/4A migrate the fastest (Fig. 1.11A). We further examined 
the TAZ activity in invasion using Matrigel. Expression of TAZ-S89A greatly 
enhanced invasion of both MCF10A (Fig. 1.11B,C) and HPNE (Fig. 1.11D,E) 
cells. In line with the observations from Fig. 1.10 and Figure 10A, non-mitotic 
phosphorylatable mutant (TAZ-S89A/4A) further increased the invading activity 
when compared to TAZ-S89A (Fig. 1.11B-E). Again, TAZ-4D-expressing cells 
(similar to control cells) possess the lowest activity in invasion (data not shown). 
Together, these data suggest that mitotic phosphorylation of TAZ inhibits cell 
motility in immortalized epithelial cells. 
 
TAZ is a transcriptional co-activator, and functions mainly through the TEAD1-4 
transcription factors in the Hippo pathway (69, 72, 73). We determined whether 
mitotic phosphorylation affects TAZ’s transcriptional activity using luciferase 
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reporter assays. As shown in Figure 5F, expression of TAZ-5A (TAZ-S89A/4A) 
significantly increased the luciferase activity compared with TAZ-S89A (Fig. 
1.11F). Expression of TAZ-4D failed to significantly induce TEAD-luciferase 
activity (data not shown). These results suggest that mitotic phosphorylation 
impairs TAZ’s transcriptional activity. Consistent with these observations, the 
target genes expression was further induced by overexpression of TAZ-5A when 
compared with TAZ-S89A (Fig. 1.11G).Collectively, these data strongly indicate 






















Figure 1.11 Mitotic phosphorylation of TAZ inhibits its oncogenic and 
transcriptional activity. 
A, Wound healing assays in MCF10A cells expressing various TAZ constructs. 
B,C, Cell invasion assays with MCF10A cells expressing vector, TAZ-S89A or 
TAZ-S89A/4A. Invaded cells were stained with DAPI and representative fields 
were shown (C). 
D,E, Cell invasion assays with HPNE cells expressing vector, TAZ-S89A or TAZ-
S89A/4A. Invaded cells were stained with DAPI and representative fields were 
shown (E). 
F, Luciferase reporter assays in HEK293T cells. Expression levels of TAZ-S89A 
and TAZ-S89A/4A are similar in all transfections (data not shown). Ctrl: control 
(empty vector); 5A: S89A/4A. Data are expressed as the mean ± s.e.m. of three 
independent experiments (each in triplicate). **: p<0.01 (TAZ5A vs TAZ-S89A)(t-
test). 
G, Quantitative RT-PCR of YAP targets in MCF10A cells expressing vector, TAZ-
S89A or TAZ-S89A/4A. Data are expressed as the mean ± s.e.m. of three 










1.3.2.7 Non-phosphorylatable (active) TAZ induces mitotic abnormalities 
We next examined whether TAZ or its phosphorylation mutants are able to 
trigger mitotic defects. MCF10A cells stably expressing vector, TAZ-S89A, and 
TAZ-5A (TAZ-S89A/4A) were used for this purpose. Consistent with our recent 
studies, immunofluoresence staining with α-tubulin and γ-tubulin showed normal 
microtubule/spindle formation and centrosome number during mitosis in most 
control cells (Fig. 1.12A). In contrast, mitotic abnormalities (disorganization of 
microtubules and formation of multipolar spindles) were detected in a significantly 
higher percentage of cells expressing TAZ-S89A, and to a greater extent in TAZ-
S89A/4A-expressing cells (Fig. 1.12A,B). Overexpression of TAZ-S89A or TAZ-
S89A/4A also induced abnormal centrosome (γ-tubulin staining) number (Fig. 
1.12A,C). Not surprisingly, massive chromosome misalignment and chromosome 
missegregation were observed in a higher percentage of TAZ-S89A- or TAZ-
S89A/4A-expressing cells when compared with vector-expressing cells (Fig. 
1.12A,D). These data suggest that ectopic expression of non-phosphorylatable 







Figure 1.12 Non-phosphorylatable TAZ induces mitotic defects in MCF10A 
cells. 
A, Representative photos of normal mitosis (vector control) and mitotic 
abnormalities (TAZ-S89A or TAZ-S89A/4A) in MCF10A cells. MCF10A cells 
stably expressing vector, TAZ-S89A, and TAZ-S89A/4A (TAZ5A) were 
established at the same time and maintained at similar passage (around 22-24 at 
the time of experiments conducted).Cells were stained with α-tubulin, γ-tubulin 
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antibodies and DAPI to visualize microtubules (red), centrosomes (green), and 
chromosomes (blue), respectively. 
B-D, Quantification of mitotic characteristics including microtubule 
organization/multipolar spindles. (B), centrosome number (C), and chromosome 
alignment. (D). Data were collected from n=106,185, and 243 mitotic cells for 
vector control, TAZ-S89A, and TAZ-S89A/4A-expressing cells, respectively. Data 
were expressed as the mean ± s.e.m. of four independent experiments. **: p< 

















Aurora kinases are important regulators of cell cycle progression and are 
potential oncogenes (74, 75). Thus, identification of modulators and/or substrates 
of Aurora kinases is important for understanding the function and mechanisms of 
action of Aurora kinase family proteins and the basic principles of cell cycle 
regulation. In fact, many regulators or substrates of Aurora kinase have been 
implicated in controlling mitotic entry, chromosome alignment/segregation, and 
cytokinesis (76). We previously showed that KIBRA is phosphorylated by Aurora 
kinases in mitosis (27). In the present study, we have further demonstrated that 
KIBRA is required for full activation of Aurora kinases during mitosis (Fig. 1.1). 
Future studies are needed to examine whether Aurora-mediated phosphorylation 
of KIBRA is involved in the mitotic defects induced by knocking down KIBRA. 
 
Both Aurora-A and Lats2 are localized to the centrosome during mitosis, raising 
the possibility that KIBRA or phosphorylated KIBRA is also localized to this 
mitotic structure, but this has not been investigated and demonstrated. 
Interestingly, a previous report showed that KIBRA associates with the 
microtubule motor protein dynein light chain 1 (24). These findings, along with 
the demonstration of mitotic defects induced by KIBRA knockdown, strongly 
suggest that KIBRA may also be required for proper construction of the mitotic 
apparatus. We are currently investigating the spatial and temporal localization of 
KIBRA and phosphorylated KIBRA, and such studies are anticipated to further 
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strengthen the importance of KIBRA in cell cycle progression, especially in 
mitosis. 
 
The mechanism through which Lats2 regulates KIBRA phosphorylation is 
currently unknown. Phosphorylation of KIBRA on Ser539 is regulated by Aurora 
kinase and PP1. Thus, it is possible that overexpression of Lats2 stimulates 
dephosphorylation of KIBRA by inhibiting Aurora kinase activity and/or activating 
PP1. However, although we showed that PP1 is required for Lats2 to inhibit 
phosphorylation of KIBRA on Ser539 (Fig. 1.4), a solid connection between Lats2 
and PP1 has not been established. We previously demonstrated that KIBRA also 
associates with PP1 (27). Therefore, it will be interesting to explore whether 
Lats2 or Lats2Δ22 affects PP1 activity or the interaction between KIBRA and 
PP1. Moreover, it is of particular interest to determine the difference between 
Lats2 and Lats1 with regards to their activity toward inhibiting the 
phosphorylation of KIBRA. 
 
We noticed that cells with Lats2 knockdown or knock-out also exhibit defects 
similar to those caused by knocking down KIBRA, including failure of centrosome 
maturation, spindle disorganization, and chromosome misalignment, which 
further supports the notion that KIBRA-Aurora-Lats2 may form a novel signaling 
axis that regulates mitosis. It will be interesting to explore to what extent these 
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proteins regulate mitosis in a mutually dependent way. Interestingly, recent 
reports have also connected other members of the Hippo pathway with mitosis. 
For example, the tumor suppressors Mst1 and Mob1 are involved in centrosome 
duplication, and Mob1 also localizes to the centrosome during mitosis (77). 
WW45 and Mst2 control centrosome disjunction and the localization of Nek2 to 
centrosomes (78). In addition, Mats (Drosophila ortholog of Mob1) is required for 
proper chromosomal segregation in developing embryos (79). Thus, it may be a 
common feature that Hippo pathway components control mitotic-related events 
and that deregulation of their function may result in mitotic defects, contributing to 
genome instability/aneuploidy and subsequent tumorigenesis. One would expect 
that YAP and TAZ, downstream effectors in the Hippo pathway, may also have a 
mitotic role. Therefore, it is worth investigating whether Hippo pathway activity is 
cell cycle-regulated.  
 
Intriguingly, recent studies have shown that most of the Hippo core tumor 
suppressor proteins, such as Mst1/2, Lats1/2, WW45, Mob1 are involved in 
regulating mitosis (9, 78, 80, 81). Furthermore, several other regulators of the 
Hippo pathway, such as Ajuba, Zyxin, as well as the effector YAP are known to 
be regulated (phosphorylated) during mitosis and they all play a role in mitotic 
progression (27, 58, 59, 61, 82-86). Therefore, these studies suggest that the 
Hippo-YAP/TAZ pathway ensures normal mitosis and deregulation of the 
pathway causes mitotic aberrations and tumorigenesis.  
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Upon treatment with anti-microtubule agents including Taxol, YAP (59, 60) and 
KIBRA (27, 58) are phosphorylated by mitotic kinases independently of the Hippo 
pathway. Another prominent change is the marked increase of Lats2 proteins in 
response to Taxol treatment (59, 87). Interestingly, induction of Lats2 and 
phosphorylation of YAP regulate Taxol-sensitivity in cancer cells (60, 87). 
Furthermore, TAZ and its downstream targets Cyr61 and CTGF have been 
shown to be important regulators for Taxol-resistance in breast cancer cells (60). 
Our current studies showed that TAZ is phosphorylated during Taxol treatment 
and this phosphorylation inhibits its transcriptional activity (Figs. 1.7,11). Taxol 
(trademark: Paclitaxel) is widely used for treating breast and ovarian cancer 
patients and drug-resistance is one of the major clinical challenges. Therefore, it 
will be interesting to determine the role of mitotic phosphorylation of TAZ in 
mediating anti-Taxol drug resistance. 
 
Although recent studies have demonstrated the important roles for TAZ in 
promoting tumorigenesis, the underlying mechanisms are largely unclear. The 
current study identified novel phosphorylation of TAZ during mitosis and 
importantly, the mitotic phosphorylation regulates TAZ’s oncogenic activity (Figs. 
1.10,11). Interestingly, TAZ-5A (a non-phosphorylatable mutant), but not TAZ-4D 
(L.Z. and J.D., unpublished observations), drives massive mitotic defects (Fig. 
1.12). Thus, TAZ may contribute to cancer development by regulating mitosis-
related events, since aberration of mitosis often causes genome 
instability/aneuploidy and subsequent tumor formation (88). 
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Our data not only reveal a new layer of regulation for TAZ’s oncogenic activity, 
but also highlight a previously unrecognized mechanism through which TAZ 
exerts its oncogenic function.  We found that mitotic phosphorylation did not 
affect TAZ’s binding with the major transcription factor TEAD1 and Lats2 kinase 
(L.Z. and J.D., unpublished observations). Thus, it is not clear how CDK1 
phosphorylation of TAZ increases its transcriptional activity. Does this 
phosphorylation regulate TAZ’s transcriptional activity with other transcription 
factors? We recently found that YAP (a paralog of TAZ) is required for the 
spindle checkpoint activation induced by Taxol (82). YAP regulates the spindle 
checkpoint through upregulating the spindle checkpoint protein BubR1 in a 
mitotic phosphorylation-dependent manner (82). Since the spindle checkpoint is 
a surveillance mechanism in mitosis (89), these studies suggest that YAP and its 
mitotic phosphorylation trigger mitotic defects through the dysregulation of the 
spindle checkpoint machinery. Surprisingly, knockdown of TAZ had no effects on 
the spindle checkpoint activation and mitotic arrest in the presence of anti-mitotic 
agents (L.Z. and J.D., unpublished observations), suggesting a distinct function 
of TAZ and YAP in mitosis. Future studies are needed to address how TAZ and 
its mitotic phosphorylation are involved in mitosis and how they promote the 
mitotic defects. Furthermore, mitotic phosphorylation activates YAP (59) and in 
contrast, TAZ is inhibited by mitotic phosphorylation regarding their oncogenic 
activity (Figs. 1.10,11). It is currently not known how TAZ and YAP achieved 
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 Functional Study of Hippo-YAP Signaling in Prostate Cancer 
This part is a modified version of the original publication:  














2.1  Introduction 
In 2014, there were 233,000 estimated new cases of prostate cancer and 29，
480 estimated deaths caused by prostate cancer in the United States. In the past 
10 years, prostate cancer remains the most common malignancy and the second 
leading cause of cancer deaths among men in the United States. The treatment 
regimens of prostate cancer are based on the stage of the disease. For localized 
cancer, the conventional treatments are surgical excision (radical prostatectomy) 
and radiotherapy. In cases of advanced or invasive cancer, including those have 
metastatic lesions, androgen deprivation therapy is the major strategy (1). 
Androgen ablation initially decreases the volume of both primary and metastatic 
lesions and reduces PSA to low or undetectable level, however, in most cases 
the tumors will recur and become chemotherapy-resistant and androgen-
independent (2, 3). This recurrence of prostate cancer is termed “castration 
resistant prostate cancer (CRPC)”, since the removal of testicular androgen by 
chemical or surgical castration does not effect as in the initial response, 
ultimately the disease will be lethal (4, 5).  
 
Circulating androgens are essential for both normal prostate development and 
the onset of prostate cancer through interactions with the androgen receptor 
(AR). Testosterone is the major androgen produced by testis and adrenal gland. 
When testosterone enters prostate cells, it is converted to dihydrotestosterone 
(DHT) by the enzyme 5-reductase. This more potent form of androgen binds to 
the AR and induces its dimerization and phosphorylation.  Then the androgen 
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receptor complex translocates into nucleus, where it binds to androgen-response 
elements in the promoter regions of target genes, and leads to biological 
responses including growth, survival and the produce of prostate-specific antigen 
(PSA).  
 
During castration-resistant progression, prostate cancer relies on various cellular 
pathways, some involving the androgen receptor and others bypassing it. In the 
former type of pathway, amplification of AR gene copy number happens in about 
one-third of CRPC patients (6-8). Another 10%–30% of tumors have mutations of 
AR that may confer increased protein stability, greater sensitivity to androgens, 
novel responses to other steroid hormones, ligand-independent activity, or 
increased recruitment of AR coactivator proteins (9-11).  In the pathways that 
bypass the androgen receptor, the loss of PTEN (phosphatase and tensin 
homolog) results in up-regulation of the Akt/mTOR signaling pathway in prostate 
cancer, primarily through activation of Akt1 (12, 13). In addition, Erk-MAPK 
signaling is also frequently activated in prostate cancer, particularly in advanced 
disease, and is often coordinately deregulated together with Akt signaling (14, 
15).  
 
In the past two decades, the use of genetically engineered transgenic and 
knockout mice has represented a major progress of prostate cancer 
investigations. A well-studied model is the TRAMP (transgenic adenocarcinoma 
of the prostate) mouse model, which carries a probasin promoter driving both 
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SV40 large T and small t antigen and results in adenocarcinoma and CRPC (16). 
Loss of Nkx3.1 and Pten showed accelerated formation of high-grade PIN 
(prostate intraepithelial neoplasia) and invasive cancer (17). Conditional deletion 
of PTEN and p53 in the prostate driven by a minimal probasin promoter driving 
Cre recombinase developed PIN and adenocarcinoma. However, none of these 
models closely mimics the human prostate cancer progression. 
 
Recent genetic mouse models and studies with cancer patients have firmly 
demonstrated the critical roles of Hippo pathway in cancer development and 
progression. For example, Mst1 and Mst2 suppress development of 
hepatocellular carcinoma (HCC) in mice (18-20). WW45 heterozygous mice and 
mice with a conditional deletion of WW45 in the liver develop osteosarcoma and 
hepatoma (21). Although mutations are rare in Hippo pathway, mutation or 
deletion of Lats2 is significant in malignant mesothelioma (22).  
 
As the main downstream effectors of the Hippo pathway, YAP and TAZ do not 
have any DNA binding domain thus they function as the transcriptional co-
activators, promoting the downstream gene expression through binding with 
multiple transcription factors.  Among these transcription factors, the TEAD/TEF 
family, which represent homologs of the Drosophila Sd protein, are the prime 
mediators of YAP/TAZ function in Hippo Signaling. The YAP/TAZ-TEAD 
transcription factor complex represents a common target of oncogenic 
transformation.  The oncoprotein YAP has been implicated in promoting several 
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types of tumor formation, such as liver and skin tumorigensis and 
rhabdomyosarcoma (23-27). Specifically, the Tet-on inducible YAP transgenic 
mice developed numerous discrete nodules in the liver after 8 weeks feeding with 
water containing doxycycline, and further developed to widespread HCC after 3 
months (24). As expected, overexpression or hyperactivation (nuclear 
localization) of YAP is frequently detected in several human malignancies 
including liver, ovarian, breast, lung and pancreatic cancer (24-26, 28-34). In 
addition to the role of Hippo-YAP signaling in cancer development, recent studies 
also implicate YAP involved in the metastatic progression of breast cancer and 
melanoma (35). Although one study have shown that TAZ overexpression was 
detected in 21% of primary breast cancers (36), a comprehensive study of TAZ 
protein expression across multiple tumor types is unavailable at present. 
 
Accumulated evidence has shown that the Hippo-YAP pathway activity is 
regulated by many cues and factors, including cell adhesion, cell polarity, contact 
inhibition/cell density, and cytoskeleton dynamics/mechanical forces (37, 38).  
Recent studies have also demonstrated that YAP/TAZ activity can be regulated 
independently of Hippo signaling and YAP/TAZ crosstalks with many other 
canonical signaling pathways including Wnt/β-catenin (39-45), TGF-β/Smad (46-
48) and Ras-ERK (34, 49, 50)  in the regulation of cancer cell proliferation, 
survival and tumorigenesis. Although YAP signaling is largely involved in 
mediating these physiological processes, the biological significance of YAP in 
prostate cancer has not been previously defined. 
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Our study is the first study that explored the functional role of YAP in prostate 
cancer cell motility, invasion and castration-resistant growth and determined the 
clinical relevance of YAP in CRPC. Our data identify YAP as a critical regulator in 
prostate cancer, especially for CRPC, providing an alternative mechanism 
underlying the development of castration-resistance of prostate tumor cells. 
 
2.2 Materials and Methods 
Expression constructs 
The pcDNA-YAP expression construct has been described (24). Point mutations 
were generated by the QuikChange Site-Directed PCR mutagenesis kit 
(Stratagene, La Jolla, CA, USA) and verified by sequencing. To make the 
retroviral-mediated YAP expression construct, the above cDNA was cloned into 
MaRXTMIV vector. The lentiviral YAP shRNA constructs and packaging vectors 
(psPAX2 and pMD2.G) were from Addgene (Cambridge, MA, USA).  
 
Cell culture and transfection 
HEK293T, HEK293GP, RWPE-1, LNCaP cell lines were purchased from 
American Type Culture Collection (ATCC, Manassas, VA, USA). HEK293T and 
HEK293GP cell lines were maintained in DMEM containing 10% FBS and L-
glutamine plus 100 units/ml penicillin and 100 µg/ml streptomycin (Invitrogen) at 
37 °C in a humidified atmosphere containing 5% CO2. The LNCap cell lines were 
maintained in ATCC-formulated RPMI-1640 Medium containing 10% FBS at 
37 °C in a humidified atmosphere containing 5% CO2. The cell lines were 
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authenticated at ATCC and were used at low (<25) passages. The LNCaP-C4-2 
and LNCaP-C81 sublines have been described (51-53). All the transient 
overexpression transfections were performed using Attractene (Qiagen) following 
the manufacturer’s instructions. Cells were harvested at 2 days post-transfection. 
RNA interference was performed using HiPerFect (Qiagen). For DNA and siRNA 
co-transfection, Attractene reagents were used. siRNA oligonucleotides were 
purchased from Dharmacom and GenePharma. YAP siRNA was synthesized by 
GenePharma based on the following target sequence (YAP-1: 5’-
CAGGTGATACTATCAACCAAA-3’; YAP-2: 5’-GACCAATAGCTCAGATCCTTT 
(selected by Invitrogen online software). R1881 was purchased from PerkinElmer 
(Waltham, MA, USA) All other chemicals were either from Sigma or Thermo 
Fisher.   
 
Retrovirus packaging and infection 
To generate wild type YAP and YAP mutant overexpression stable cell lines, 
retrovirus   infection was performed by transfecting HEK293GP cells with empty 
MXIV-neo vector or MXIV-neo wild type YAP or YAP mutant constructs, following 
the company’s instructions (Oligoengine). Each plasmid was co-transfected with 
a construct expressing the VSV-G gene into the virus packaging cell line 
HEK293GP to produce retrovirus expressing wild type YAP or YAP mutant. The 
obtained retroviral supernatant was further filtered with 0.45µM filter and used to 
infect the RWPE-1 and LNCaP cells with polybrene (Millipore) with the final 
concentration of 10 µg/ml. At 24hours after infection, virus supernatant was 
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replaced with fresh growth medium. The transduced cells were then selected at 
800 µg/ml of neomycin (at 48hours post-infection) to establish stably expressing 
YAP or YAP mutant cell lines. Western blot was used to test the expression level 
of YAP. 
 
Lentivirus packaging and infection 
The LNCap-C4-2 cells were stably transfected with YAP shRNAs (purchased 
from Addgene). Briefly, lentivirus infection was performed by transfecting 
HEK293T cells with pLKO1-shYAP1 and pLKO1-shYAP2, following the 
company’s instructions (Oligoengine). The plasmid (2.5 µg) was co-transfected 
with the construct expressing psPAX2 (2.0µg) and pMD2.G (1.0µg) gene into the 
virus packaging cell line HEK293T to produce lentivirus expressing YAP shRNA 
with puromycin as the selectable marker, when HEK293T cells reached 50% 
confluence. At 16hours after transfection, the medium was replaced and HEPES 
(10 mM) and Sodium Butyrate (10 mM) were added to increase the half-life and 
production of the virus. At 48 hours after transfection, the obtained lentiviral 
supernatant was collected and further filtered with a 0.45 µM filter and used to 
infect the LNCaP-C4-2 cells with polybrene (Millipore, Billerica, MA, USA) in the 
presence of 10 μg/ml of polybrene. At 24hours after infection, the virus 
supernatant was replaced with fresh growth medium. The transduced cells were 
then selected with puromycin (2μg/ml) to establish cell lines in which YAP 
expression was stably knocked down. Western blot was used to test the 
expression level of YAP. 
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Quantitative real time-PCR 
Total RNA isolation, RNA reverse transcription and quantitative real time-PCR 
were done as described previously (54). Other primer sequences are as follows: 
TEAD1: cttgaatgtgcaatgaagcg (forward, F), cgaagtttgcctcggactc (reverse, R); 
TEAD2: ctcactccgtagaagccacc (F), tgccttcttcctggtcaagt (R); TEAD3: 
gcaccttcttccgagctaga (F), tacggccgaaatgagttgat (R); TEAD4: 
gctccactcgttggaggtaa (F), cttagcgcacccatccc (R);  YAP: acgttcatctgggacagcat 
(F), gttgggagatggcaaagaca (R); TAZ: attcatcgccttcctagggt (F), 
ggctgggagatgaccttcac (R);  CTGF: ttggcaggctgatttctagg (F), 
ggtgcaaacatgtaacttttgg (R); ITGB2: actcctgagagaggacgcac (F), 
cagggcagactggtagcaa (R); ANKRD1: gtgtagcaccagatccatcg (F), 
cggtgagactgaaccgctat (R); Cyr61: cccgttttggtagattctgg (F), gctggaatgcaacttcgg 
(R); SOX4: aatgtatgtttccccctccc (F), tcgctgtcgggtctctagtt (R); Survivin: 
cgaggctggcttcatccact (F), acggcgcactttcttcgca (R); PSA: atatcgtagagcgggtgtgg 
(F), tcctcacagctgcccact (R); NKX3.1: cagataagaccccaagtgcc (F), 
cagagccagagccagagg (R); KLK2: tgtcttcaggctcaaacagg (F), 
gtacagtcatggatgggcac (R); PGC-1: ctgctagcaagtttgcctca (F), 
agtggtgcagtgaccaatca (R).  
 
Cell fractionation assay 
Cell fractionation assays were done by NE-PER Nuclear and Cytoplasmic 
Extraction Reagents following the manufacturer’s instructions (Thermo 
Scientific/Pierce, Rockford, IL, USA). 
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Antibodies and Western blot analysis 
The YAP antibodies from Cell Signaling Technology (#4912, Danvers, MA, USA) 
and Abcam (52771, Cambridge, MA, USA) were used for Western blotting 
throughout the study. Anti-β-actin, anti-androgen receptor, anti-ERK1/2, anti-Akt, 
anti-GSK3β, anti-β-catenin, anti-RSK1 and anti-RSK2 antibodies were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Mst1, anti-Mst2, anti-
Lats1 and anti-Lats2 antibodies were from Bethyl Laboratory (Montgomery, TX, 
USA). Anti-phospho-YAP S127, anti-phospho-Akt T308, anti-phospho-Akt S473, 
anti-phospho-GSK3β S9, anti-phospho-ERK1/2, anti-phospho-Mst2 T180, anti-E-
cadherin, anti-vimentin and anti-PARP antibodies were from Cell Signaling 
Technology. Mouse monoclonal antibody against N-cadherin was provided by Dr. 
Keith Johnson (University of Nebraska Medical Center) (55). Anti-phospho-RSK 
S380 antibody was from Biolegend (San Diego, CA, USA). Anti-NF2 and anti-β-
tubulin antibodies were from Sigma (St. Louis, MO, USA). The cells were 
harvested and cell lysate were prepared by 2XSDS lysis buffer. The proteins 
were separated on SDS polyacrylamide gels and transferred onto PVDF 
membranes (Millipore). HRP-conjugated anti-mouse or anti-rabbit IgG were from 
Pierce. ECL and SuperSignal West Pico Chemiluminescent substrate kits (Pierce) 
were used as HRP substrates. 
Cell proliferation and anchorage-independent growth assays 
For cell proliferation assays, 5,000 (LNCaP-C4-2) or 10,000 (LNCaP) cells were 
seeded in wells of a 24-well plate in triplicate. Cells were counted by a 
hemocytometer (Thermo, Waltham, MA, USA) and proliferation curves were 
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made based on cell numbers of each well from three independent experiments. 
Soft agar assays were conducted in 6-well plates. The base layer of each well 
consisted of 1.5ml with final concentrations of 1 x media and 1% agarose. Plates 
were chilled at room temperature until solid, at which point a 2 ml growth medium 
with 0.5% agarose layer was poured, consisting of cells suspended (LNCaP-C4-
2 cells: 5000 cells per well, LNCaP cells: 1X104 cells per well). Plates were again 
chilled at room temperature until the growth layer congealed. A further 1 ml of 1x 
culture media without agarose was added on top of the growth layer. The growth 
medium was changed every week for 3-4 weeks, after which colonies were fixed 
with 3.7% PFA and stained with 0.005% crystal violet for 1 minute followed by 
PBS wash for 3 times of 5 minutes each. A picture was taken and total colonies 
were counted.  Data were obtained from three independent experiments. 
 
Cell migration and invasion assays 
In vitro analysis of invasion and migration was assessed using the BioCoat 
invasion system (BD Biosciences) and Transwell system (Corning), respectively, 
according to the manufacturer's instructions. The cells were trypsinized and 
resuspended in the medium without serum and/or growth factor at the indicated 
concentration (RWPE-1: 1.0X105/well, LNCaP 5.0X104/well, C4-2: 5.0X104/well 
for migration assay; RWPE-1: 5.0X104/well, LNCaP 5.0X104/well, C4-2: 
5.0X104/well for invasion assay). 600 µl of basal medium with 10%FBS was 
added to the bottom of the migration assay chamber, and 750 µl for BioCoat 
invasion chamber. The insert was carefully placed into each well to avoid leaving 
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a bubble between insert and the medium in the bottom chamber. 100 µl or 500 µl 
of the above mentioned cell suspension was added to the insert for migration and 
invasion assay, respectively. After the incubation at 37°C for 18 to 24 hours, the 
plate was removed from the incubator. The cells were fixed with 3.7% PFA and 
the cells inside the inserts were removed with cotton swabs. Then, the invasive 
and migratory cells were stained with ProLong® Gold Antifade Reagent with 
DAPI. The relative invading and migrating rate were calculated by the number of 
cells invading and migrating through the membrane, divided by the number of 
cells that invaded and migrated in the control group. 
 
Immunohistochemistry (IHC) staining 
Tissue microarray slides (TMA) were obtained from the Prostate Cancer 
Biorepository Network (PCBN, New York University site). The TMA consists of 7 
naïve (hormone responsive) and 13 castration-resistant prostate cancer tumors 
collected from 1983 to 2002 at New York University Langone Medical Center. 
Slide deparaffinization, antigen retrieval, and blocking were performed as we 
have described (24). The sections were then stained with anti-YAP antibody (Cell 
Signaling #4912, at 1:100 dilutions) using a Histostain-Plus IHC kit following the 
manufacturer’s instructions (Invitrogen, Grand Island, NY, USA). Cell nuclei were 
stained with Hematoxylin. Ventana iScan HT (Roche) was used for slide 
scanning with a 20X lens. The staining results were independently evaluated by 
three researchers including two pathologists (S.M.L. and K.F.). Both the YAP 
staining intensity (a scale of 0 to 3 was used: 0-negative, 1-weak, 2-moderate, 
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and 3-strong) and nuclear localization (the percentage of tumor cell nuclei 
stained, 0-no staining, 1-≤10%, 2-10-50%, and 3->50%) were scored (56). 
 
Mouse xenograft Studies 
For in vivo xenograft studies, LNCaP cells expressing vector or YAP in 50% 
Cultrex (Trevigen, Gaithersburg, MD, USA) (2.0x106 each line/0.1 ml) were 
subcutaneously injected into the left flank of 3-month-old castrated male SCID 
mice (Charles River, Wilmington, MA, USA). Six or nine animals were used for 
control (vector) and experimental (YAP) groups, respectively. Mice were 
euthanized at 8 weeks post-injection and the tumors were excised and fixed for 
subsequent histopathological examination and IHC analysis. The animals were 
housed in pathogen-free facilities. All animal experiments were approved by the 
University of Nebraska Medical Center Institutional Animal Care and Use 
Committee.  
 
Generation of prostate-specific Tet-on inducible YAPS127A transgenic mice 
The Tet-on inducible system was used to generate prostate-specific inducible 
YAP-S127A mice. We crossed the PB-rtTA mice to Tet-on YAP-S127A mice to 
generate pups with both PB-rtTA and Tet-YAPS127A alleles. Since rtTA (reverse 
tetracycline transactivator) is located downstream of the PB promoter, it is 
specifically expressed in prostate tissue. As a result, in the presence of 
doxycycline (fed with drinking water), rtTA binds to the tetracycline response 
element and produces high level of YAP-S127A. Prostate of different ages of 
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these male mice were dissected and histological analysis were performed to 
check the formation of prostatic intraepithelial neoplasia (PIN) and 
adenocarcinoma. 
 
Generation of prostate-specific MST1/2 knockout mice 
The Cre-LoxP system was used to generate mice with prostate-specific deletion 
of Mst1/2. The Mst1 flox/flox; Mst2 flox/flox mice were mated with male PB-Cre mice. 
PCR genotyping was used to determine the genotype of the offspring. Then the 
male Mst1 flox/+; Mst2flox/+;Cre+ mice were mated with Mst1 flox/flox ; Mst2 flox/flox mice 
to generate the homozygous mice with prostate-specific deletion of Mst1/Mst2. 
Prostate at different age of these male mice were dissected and histological 
analysis were performed to check the formation of PIN and adenocarcinoma. 
 
Mouse genomic DNA purification 
3-week-old mice were weaned and 1/3-1/2 cm mice tails were cut for genomic 
DNA purification. To each tail, 500ml of tail digestion buffer was added (which 
has been supplemented with proteinase K at a final concentration of 0.5 mg/ml) 
and placed at 55℃ for 16-24 hours. After vigorously shaking tubes for about 15 
seconds, tubes were centrifuged at top speed for 15 minutes. Then the 
supernatant was transferred to new micro-tubes containing 500ul isopropanol. 
After 5 minutes incubation at room temperature, tubes were centrifuged at top 
speed for 4 minutes.  The DNA pallets were washed twice by adding 100ul 70% 
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ethanol. Then add 200ul ddH2O and incubate for 1 hour at 55℃ to dissolve the 
DNA. Then DNA was ready to use for PCR genotyping. 
 
Genotyping 
The PCR genotyping was performed using Promega GoTaq Flexi DNA 
polymerase kit. All PCR reactions were set in the following 20ul system: DNA 2ul, 
5 X Promega buffer 4ul, 25mM Mg2+ 1.6ul, 2.5mM dNTP 2ul, 10uM mixed primer 
4ul, Promega enzyme 0.2ul, ddH2O 6.2ul.  
 
Tissue processing 
Mouse tissue was fixed in 3.7% PFA for 16h and then transferred to 70% ethanol. 
Tissue embedding and slides preparation were performed by Tissue Science 
Facility in UNMC. 
 
Statistical analysis  
Data were analyzed using a two-tailed, unpaired Student’s t-test. The Wilcoxon 
rank sum test was used to compare the IHC staining data between groups. A P 








The Hippo Pathway Effector, YAP, Regulates Motility, Invasion and 
Castration-Resistant Growth of Prostate Cancer Cells. 
2.3.1 Upregulation and activation of YAP in prostate castration-resistant 
tumors 
To explore the functional significance of hippo pathway in prostate cancer, we 
collected both clinical prostate normal and cancer tissues, and our data showed 
that YAP was highly expressed in  nearly all of the tumor samples examined 
whereas relatively lower level in normal tissues (Fig. 2.1A). Interestingly, the 
upstream tumor suppressor Mst1 expression was detected in only one of nine 
tumor samples but three of the four normal samples (Fig. 2.1A). This suggests 
that hippo pathway is dysregulated in human prostate cancer. We further mined 
YAP expression data from large scale studies of prostate cancer. These data 
confirmed that YAP mRNA was significantly high in CRPC or metastatic prostate 
tumors compared to primary tumors (Fig. 2.1B,C). 
 
YAP is overexpressed and/or hyperactivated (as shown by nuclear localization) 
in prostate primary tumor samples (24, 32). However, it is not known to what 
extent YAP activity/expression correlates with prostate castration resistance. To 
determine the functional relevance of YAP in CRPC in the clinical setting, we 
obtained tissue microarrays containing naïve (hormonal responsive) and 
castration-resistant prostate tumors and performed immunohistochemical (IHC) 
staining. Immunostaining demonstrated that overall YAP expression was 
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relatively weak in naïve prostate tumors (Fig. 2.2A-A’’, n=7) and no single case 
was scored moderate or strong for YAP staining (see ‘Materials and Methods’). 
Importantly, we observed dramatic upregulation of YAP in most hormonal 
therapy resistant tumor samples (Fig. 2.2B-E, n=13). Nine of the resistant tumors 
showed moderate-strong staining and 4 of them had weak staining (compared 
with all of the naive tumors showing weak to no staining) (p=0.003, resistant 
versus naive). Furthermore, strong nucleus-localized (hyperactive) YAP staining 
was detected in 5 of the resistant tumors (Fig. 2.2B-B’’, D-D’’ and F) (p=0.001, 
resistant versus naive). These data indicates that YAP may function as a critical 











Figure  2.1  Upregulation of YAP in prostate tumors. 
A. YAP and Mst1 protein levels in prostate normal and tumor samples. 
B, Relative YAP mRNA levels in localized (primary) tumors and CRPC (resistant). 
Data were mined from Grasso et al., 2012. N=60 (primary) and 36 (resistant). ***: 
p<0.001 (t-test). 
C, Relative YAP mRNA levels in primary and metastatic (Met) tumors (most 
metastases are castration resistant). Data were retrieved from Gene Expression 




       
Figure 2.2 Upregulation and activation of YAP in castration-resistant 
prostate tumors. 
A-A’’, Representative photos of immunostaining for YAP in naïve (hormonal 
responsive) prostate tumors.  
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B-B’’, C-C’’, and D-D’’ Representative photos of YAP IHC staining in hormonal 
therapy-resistant prostate tumors. 
E, Quantification of YAP IHC staining intensity in naive and castration-resistant 
prostate tumors. Four resistant cases (3254108156, 8322079241, 8842201759, 
6756440716) were scored low, five resistant cases (4024863604, 5962887148, 
3698735602, 9182583214, 2667199309) were scored moderate and four 
resistant cases (8063595154, 4976472144, 4729101711, 7346843168) were 
scored high for YAP staining. All naïve tumors samples have no to low YAP 
staining (4481786650, 2667199309, 8743000808, 4599423355, 8365207463, 
8315345132, 2667199309). 
F, Quantification of YAP nuclear localization based on IHC staining in naive and 
castration-resistant prostate tumors. Four resistant cases (3254108156, 
8322079241, 7346843168, 6756440716) were scored low, four resistant cases 
(8842201759, 4024863604, 4729101711, 2667199309) were scored moderate 
and five resistant cases (5962887148, 3698735602, 8063595154, 9182583214, 
4976472144) were scored high for YAP nuclear staining. All naïve tumors 
samples have no to low nuclear YAP staining.  ***: p<0.001; **: p<0.01. 







2.3.2 YAP transforms prostate epithelial cells and promotes cell motility 
and invasiveness 
Previous studies showed that YAP overexpression induced transformation of 
immortalized pancreatic and mammary epithelial cells (24, 26, 32). To investigate 
the biological significance of YAP overexpession/hyperactivation in prostate 
cancer, we first tested the role of YAP in RWPE-1 cells (immortalized prostate 
epithelial cells). As shown in Figure 3, ectopic expression of YAP stimulated cell 
proliferation and induced cellular transformation in RWPE-1 cells (Fig. 2.3A-D). 
As expected, the expression of the constitutively active YAP-S127A (S127 is the 
main Hippo-mediated phosphorylation site of YAP) mutant enhanced RWPE-1 
cell proliferation and transformation to a greater extent than wild type YAP (Fig. 
2.3B-D). YAP expression causes epithelial-mesenchymal transition (EMT) in 
mammary epithelial cells (MCF10A) (26, 32). Surprisingly, YAP transformed 
prostate cells without inducing an EMT as the levels of E-cadherin (epithelial 
marker) and vimentin (mesenchymal marker) remained unchanged in the 
presence of YAP activation (Fig. 2.4D). Consistent with this observation, YAP 
was not sufficient to induce a full EMT in a non-transformed mammary epithelial 
cell line (NMuMG) (35). 
 
Over 90% of cancer deaths are due to metastasis rather than to primary tumors 
(57, 58). Migration and invasion are essential steps for primary tumor cells to 
metastasize and grow (58-60). We therefore examined the role of YAP in 
prostate cell motility. Interestingly, overexpression of YAP or YAP-S127A also 
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significantly promoted cell migration (Fig. 2.4A) and invasion (Fig. 2.4B, C) in 
immortalized prostate epithelial cells. Next, we further explored whether 
enhanced expression of YAP stimulates migration and invasion in prostate 
cancer (LNCaP) cells. Similarly, YAP or YAP-S127A overexpression resulted in a 
significant increase in number of LNCaP cells that invaded through Matrigel and 
migrated through filters compared to vector control cells, respectively (Fig. 2.5A-






















Figure 2.3 YAP promotes cell proliferation and cellular transformation of 
RWPE-1 cells.  
A, Establishment of RWPE-1 cell lines stably expressing YAP. 
B, Expression of YAP/YAP-S127A stimulates proliferation in RWPE-1 cells.  











Figure 2.4 YAP promotes migration and invasion in RWPE-1 cells. 
A-C, Cell migration (A) and invasion (B) assays with RWPE-1 cells expressing 
vector, YAP or YAP-S127A constructs. Migrating and invading cells were stained 
with DAPI and representative fields are shown (C). Quantitative data are 
expressed as the mean ± s.e.m of three independent experiments. ***: p<0.001, 
**: p<0.01, *: p<0.05 (t-test). 
D, Westen blotting analysis with the indicated antibodies in YAP-expressing 







Figure 2.5 YAP promotes migration and  invasion in LNCaP cells. 
A, Establishment of LNCaP cells expressing vector, YAP or YAP-S127A. 
B-D, Cell invasion (B,C) and migration (B,D) assays with LNCaP cell lines 










2.3.3 YAP promotes castration-resistant growth of LNCaP cells 
Most prostate cancer patients with metastatic disease progress to CRPC. We 
next assessed whether YAP expression is sufficient to induce castration-resistant 
growth in LNCaP cells, which grow completely in an androgen-sensitive/-
dependent manner. YAP overexpression stimulated proliferation of LNCaP cells 
(Fig. 2.6A, B). Interestingly, the most significant change in these cells upon YAP 
expression was the ability to proliferate normally under androgen-deprivation 
conditions (using charcoal-stripped serum [CSS] to deplete the media of 
androgens), in contrast, the control parental cells stopped dividing without 
androgen (Fig. 2.6A, B). These data indicate that enhanced expression of YAP 
was sufficient to convert LNCaP cells from androgen-sensitive to castration-
resistant. 
 
YAP was able to induce Akt and ERK activation in a cellular context-dependent 
manner (49, 50). Interestingly, we also detected moderate but reproducible 
increased phosphorylation of Akt on T308 (but not S473) upon YAP expression 
(Fig. 2.6C). Both Akt and ERK were strongly activated upon androgen depletion 
(Fig. 2.6C), suggesting that multiple cellular pathways are involved in prostate 
cancer cell survival upon androgen deprivation. 
 
TEAD1-4 (TEA domain containing protein) are the major transcriptional factors of 
the Hippo pathway. Most of the known YAP/TEADs targets including ANKRD1 
(ankyrin repeat domain 1), SOX4 (SRY(sex determining region Y)-box 4), CTGF 
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(connective tissue growth factor) and Cyr61 (cysteine-rich angiogenic inducer 61) 
were induced by YAP expression in LNCaP cells (Fig. 2.7A), indicating that YAP 
signaling is on in LNCaP-YAP cells. Survivin and ITGB2 (integrin beta 2) were 
not induced by YAP-overexpressing LNCaP cells (data not shown).  
 
We further explored whether YAP could regulate androgen signaling activity. 
Indeed, the AR (androgen receptor) targets PSA (prostate specific antigen), 
NKX3.1 (NK3 homeobox 1), PGC-1(Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha) and KLK2 (Kallikrein-2) were all greatly induced by 





















Figure 2.6 YAP promotes androgen-insensitive growth and Akt activation in 
LNCaP cells. 
A, Representative photos of LNCaP cells expressing vector or YAP that have 
been cultured under normal (FBS) or androgen deprivation (CSS) media for 3 
(FBS) or 5 (CSS) days. FBS: fetal bovine serum; CSS: charcoal-stripped serum. 
B, Cell proliferation curve for various LNCaP cells.  
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C, LNCaP cells expressing vector or YAP were cultured under normal (FBS) or 
androgen deprivation (CSS) media for 3 days. The total lysates were probed with 




























Figure 2.7 YAP induces its targets and AR activation in LNCaP cells. 
A, Relative mRNA levels of known targets of YAP (by quantitative RT-PCR) in 
LNCaP cells expressing vector or YAP.  
B, Relative mRNA levels of known targets of androgen receptor (by quantitative 
RT-PCR) in LNCaP cells expressing vector or YAP. Quantitative data are 
expressed as the mean ± s.e.m of three independent experiments. ***: p<0.001, 








2.3.4 Upregulation of YAP in castration-resistant prostate cancer cells 
We further assessed the extent to which YAP expression/activity is altered during 
androgen-sensitive to castration-resistant progression. For this purpose, we took 
advantage of a well-established prostate cancer cell model system. LNCaP cells 
grow slowly and completely rely on androgen, whereas LNCaP-C81 and LNCaP-
C4-2 sub-lines (both of which are castration-resistant) grow aggressively even 
under androgen-deprivation conditions. These cancer cell models closely 
represent the transition of the initial androgen-sensitive disease to castration-
resistant state (61, 62). Interestingly, we found that, compared to LNCaP cells, 
YAP expression levels were dramatically upregulated in both LNCaP-C4-2 and 
LNCaP-C81 castration-resistant cells (Fig. 2.8A). Phosphorylation of YAP on 
S127 (the major phosphorylation site for the Hippo pathway) was proportionally 
increased. Cell fractionation assays confirmed that the cytoplasmic-nuclear 
localization of YAP was not significantly altered (Fig. 2.8B). In line with this 
observation, no change was detected in the expression and activity of upstream 
Hippo core components (Fig. 2.8A and data not shown). Consistent with previous 
studies (63), AR levels were increased in LNCaP-C4-2 and LNCaP-C81 cells 
compared to parental LNCaP cells (Fig. 2.8A).  Finally, qRT-PCR showed that 
YAP but not its paralog TAZ mRNA levels were significantly elevated in LNCaP-
C4-2 and LNCaP-C81 cells, indicating that transcriptional regulation was involved 
in YAP upregulation (Fig. 2.8C and data not shown). Consistently, YAP targets 
were induced in LNCaP-C4-2 cells (Fig. 2.8D). TEAD4 but not TEAD1-3 mRNA 
was upregulated in LNCaP-C4-2 cells (Fig. 2.8E). YAP protein stability was 
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similar in both LNCaP and LNCaP-C4-2 cells (data not shown). Together, these 
results suggest that YAP was transcriptionally upregulated during the transition of 























Figure 2.8 YAP is upregulated in castration-resistant prostate cancer cells. 
A, LNCaP (androgen-sensitive) and LNCaP-C81/LNCaP-C4-2 (castration-
resistant) cell lysates were probed with the indicated antibodies. SE: short 
exposure; LE: long exposure (A,B). 
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B, Cell fractionation assay in LNCaP and C4-2 cells. The cells were harvested at 
70-80 percent confluence. β-tubulin and PARP serve as cytoplasmic and nuclear 
markers, respectively. C: cytoplasmic; N: nuclear. 
C,D, Quantitative RT-PCR of YAP and its known targets in LNCaP and 
castration-resistant sublines. 
























2.3.5 YAP promotes castration-resistant growth in vivo 
We next evaluated the influence of YAP on castration resistance in animals. 
LNCaP-vector control and –YAP-expressing cells were subcutaneously 
inoculated into castrated male mice (SCID).  As expected, most of the mice 
(except one) injected with LNCaP-vector cells did not form palpable tumors (n=6). 
However, about 67% (6/9) mice injected with LNCaP-YAP cells grew large 
tumors at the end point of the experiment (Fig. 2.9A,B). The tumors on the mice 
harboring YAP-expressing LNCaP cells were visible at one month post-injection 
(data not shown). Histopathological examination revealed extensive tumor 
necrosis and hemorrhage (Fig. 2.9C, H&E staining), which is an indicator of 
aggressiveness. Most of these tumor cells express AR and YAP (Fig. 2.9C). 
These data strongly suggest that YAP confers castration-resistant growth of 










Figure 2.9 YAP confers castration resistance in vivo. 
A, Castrated male SCID mice were implanted LNCaP-vector (top 6 mice) or  
LNCaP-YAP-expressing (bottom row) cells and photographed at 8 weeks post 
injection.  T marks the tumor-harboring mice. 
B, Tumor incidence of mice in A. 
C, Hematoxylin and Eosin (H&E) and IHC staining of androgen receptor (AR) 
and YAP.  T: tumor area; N: necrotic area. 
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2.3.6 YAP knockdown impairs migration and invasion in castration-
resistant prostate cancer cells 
To explore the biological significance of YAP upregulation in castration-resistant 
prostate cancer cells, we reduced YAP expression by shRNA (constitutive) or 
siRNA (transient) in LNCaP-C4-2 cells (Fig. 2.10A,B). Using Transwell and 
Matrigel assays, we demonstrated that YAP knockdown greatly impaired 
migration and invasion in LNCaP-C4-2 prostate cancer cells (Fig. 2.10C-J). 
These data, together with gain-of-function of YAP (Figs. 2.3-7), suggest that YAP 


















Figure 2.10 YAP knockdown in LNCaP-C4-2 cells impairs cell migration and 
invasion. 
 A, Establishment of cells stably expressing shRNA vector, and shRNAs against 
YAP (shYAP#1 and shYAP#2) in LNCaP-C4-2 cells.  
B, LNCaP-C4-2 cells were transiently transfected with control siRNA or siRNA 
targeting YAP and YAP expression were analyzed by Western blotting. 
C-F, Cell migration and invasion assays with LNCaP-C4-2 cells established in A. 
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G-J, Cell migration and invasion assays with LNCaP-C4-2 cells transfected with 
siRNA in B.  Cell migration assays with Transwell and invasion assays with 
Matrigel were performed as we previously described(64). Migrating and invading 
cells were stained with DAPI, and representative fields are shown. Data are 
expressed as the mean ± s.e.m. of three independent experiments. ***: p<0.001, 




















2.3.7 YAP is essential for castration-resistant growth of prostate cancer 
cells 
The upregulation of YAP in castration-resistant cell lines led us to further 
determine whether YAP is required for growth without androgens in these cells. 
Under normal growth conditions, LNCaP-C4-2 cells with YAP knockdown 
showed only moderately slower proliferation than control LNCaP-C4-2 cells with 
YAP expression (Fig. 2.11A, top panels, B). However, while LNCaP-C4-2 cells 
were still able to proliferate (albeit at a slow rate) in the absence of androgens 
(CSS media), YAP knockdown cells failed to divide under androgen deprivation 
conditions (Fig. 2.11A,B). Consistent with this observation, LNCaP-C4-2 cells 
with reduced YAP form colonies well in soft agar with complete serum (Fig. 
2.11C,D); however, these cells failed to grow under CSS conditions (Fig. 
2.11E,F). Again, LNCaP-C4-2 control cells, but not LNCaP-C-2 cells lacking YAP, 
formed colonies even when androgens were removed (Fig. 2.11E,F). In total, 
these studies implicate that YAP is essential for castration-resistant growth of 
prostate cancer cells. 
 
Consistent with our observations that YAP activated AR targets (Fig. 2.7B), YAP 
knockdown reduced basal levels of PSA and NKX3.1 mRNA and partially 
blocked the AR targets induced by R1881 (Fig. 2.12), further suggesting that 






Figure 2.11 YAP is required for castration-resistant growth of LNCaP-C4-2 
cells. 
A, Representative photos of LNCaP-C4-2 cells expressing control shRNA or YAP 
shRNA that have been cultured under normal (FBS) or androgen deprivation 
(CSS) medium for 5 days. FBS: fetal bovine serum; CSS: charcoal stripped 
serum. 
B, Cell proliferation curve of various LNCaP-C4-2 cells. 
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C-F, Anchorage-independent growth assay of LNCaP-C4-2 cells in soft agar 


















Figure 2.12 YAP partially blocks the AR targets induced by androgen 
analog. 
Quantitative RT-PCR of YAP, PSA and NKx3.1 in LNCaP-C4-2 cells. Control and 
YAP knockdown cells lines were cultured in serum-free medium for 24 h and 
treated with or without R1881 (1 nM) for an additional 24 h. Data were derived 
from three independent experiments and expressed as mean ± s.e.m. *: p<0.05; 










2.3.8 YAP is required for ERK-RSK signaling activation upon androgen 
depletion in LNCaP-C4-2 cells 
We next explored the downstream signaling of YAP in castration-resistant growth 
of prostate cancer cells. The PTEN/Akt axis and MEK-ERK signaling are critical 
regulators in prostate tumor survival and progression (13, 65). Both Akt and 
MEK-ERK pathways have been recently linked with YAP activity (34, 49, 50, 66). 
Interestingly, we found that both Akt and ERK-RSK signaling pathways were 
strongly activated upon androgen depletion (Fig. 2.13A,B), suggesting that 
LNCaP-C4-2 cells proliferated without androgen, at least in part, by activating 
these survival pathways. Importantly, ERK1/2 and downstream RSK1/2 
activation (revealed by phosphorylation) was largely blocked in YAP knockdown 
cells when androgens were removed (Fig. 2.13B). However, Akt activity was only 
moderately reduced when YAP was knocked down (Fig. 2.13A). Together, these 
data suggest that YAP is required for ERK-RSK activation in LNCaP-C4-2 cells 
under androgen depletion conditions. 
 
To determine the functional role of ERK activation upon androgen depletion, we 
inhibited MEK-ERK signaling with the inhibitor U0126 and analyzed migratory 
and invasive activity in LNCaP-C4-2 cells. ERK inhibition partially suppressed 
migration under normal conditions and to a greater extent in media without 
androgens (Fig. 2.14A,B). Interestingly, treatment with U0126 had no effect on 
invasion under complete media, however, U0126 greatly impaired the invasive 
ability of LNCaP-C4-2 cells under androgen-deprivation conditions (Fig. 2.14C,D). 
117 
 
As expected, knockdown of YAP significantly reduced migration and invasion in 
LNCaP-C4-2 cells (Fig. 2.14A-D). Taken together, our data indicate that ERK 
activation (probably downstream YAP) is essential for LNCaP-C4-2 cells to 
























Figure 2.13 YAP is required for ERK-RSK activation upon androgen 
depletion in LNCaP-C4-2 cells. 
A,B, Cells were harvested at day 3 under normal (FBS) or androgen-depleted 









Figure 2.14 MEK-ERK inhibitor largely reduces migration and invasion 
ability of LNCaP-C4-2 cells under androgen-deprivation condition. 
A-D, Cell migration (A,B) and invasion (C,D) assays under normal (FBS) and 
androgen-deprivation (CSS) conditions with or without MEK-ERK inhibitor U0126. 
FBS: fetal bovine serum; CSS: charcoal stripped serum. ***: p<0.001(t-test); **: 























2.3.9 Activated YAP promotes mouse prostate cell proliferation at early age 
but is not sufficient to promote tumorigenesis in the mouse prostate 
Having established the biological function of YAP in prostate tumorigenesis and 
CRPC in cell culture and immunodeficient mouse, we further explored role of 
Hippo-YAP signaling in prostate tumorigenesis by genetic transgenic mouse 
models. First, we want to examine whether activated YAP is sufficient to induce 
mouse prostate tumorigenesis or PIN. We crossed the PB-rtTA male mice to Tet-
on YAP-S127A female mice to generate prostate-specific bi-transgenic mice (Fig. 
2.16). Since rtTA is located downstream of the PB promoter, it is specifically 
expressed in prostate tissue. As a result, in the presence of doxycycline 
(administered through drinking water), rtTA binds to the tetracycline response 
element and produces high levels of hyper-active YAP-S127A (Fig. 2.16).  
 
After 10 days induction of doxycycline, activated YAP is more obviously detected 
in the epithelial cells of mice prostate compared to the control mice, and ki67 
staining showed increased proliferating cells (Fig. 2.17A). At 1 month, YAP is 
more dramatically expressed in the transgenic mice prostate compared to the 
control mice, and also more proliferating cells were detected (Fig. 2.17B), 
indicating YAP stimulates prostate epithelial cell proliferation at the early state of 
prostate development. However, after 14 months induction, we did not observe 
any PIN lesion or adenocarcinoma formation in the mouse prostate although 
YAP is still highly expressed (Fig. 2.18), suggesting that YAP is not sufficient to 


















Figure 2.17 Doxycycline induces YAP expression and epithelial cell 
proliferation at early stage. 
A, Adult single (left) or double (right) transgenic mice were fed with 
Doxycycline water for 10 days, and prostate tissue were analyzed for 
histology. YAP or ki67 IHC staining were performed. 
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B, Adult single (left) or double (right) transgenic mice were fed with 
Doxycycline water for 1 month, and prostate tissue were analyzed for 




















Figure 2.18 Activated YAP is not sufficient to promote tumorigenesis in the 
mouse prostate. 
Adult single (left) or double (right) transgenic mice were fed with Doxycycline 
water for 14 months, and prostate tissue were analyzed for histology. 









2.3.10 MST1/2 deletion is not sufficient to promote tumorigenesis in the 
mouse prostate 
We further explored whether deletion of tumor suppressor genes MST1/2 is able 
to promote tumorigenesis in the mouse prostate. The Mst1flox/flox; Mst2flox/flox mice 
were mated with male PB-Cre mice (Fig. 2.19). PCR-based genotyping was used 
to determine the genotype of the offspring. Homozygous prostate-specific 
deletion of Mst1/Mst2 were generated by breeding male PB-Cre+; Mst1flox/flox; 
Mst2flox/flox to Mst1flox/flox; Mst2flox/flox mice. Littermates without PB-Cre were used 
as controls. 
 
As shown in (Fig. 2.20A), 45 days deletion of MST1/2 in prostate increased cell 
proliferation indicated by ki67 staining. After 1 year deletion of MST1/2, still no 
PIN or adenocarcinoma observed in the mouse prostate (Fig. 2.20B). Our results 
suggest that specific deletion of MST1/2 in the prostate promotes cell 






























Figure 2.20 MST1/2 specific deletion is not sufficient to promote 
tumorigenesis in the mouse prostate. 
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A, Adult control (left) or prostate specific MST1/2 deletion (right) mice with 
conditional MST1/2 knockout for 45 days, and prostate tissue were analyzed 
for histology. MST1/2 or ki67 IHC staining were performed. 
B, Adult controls (left) or prostate specific MST1/2 deletion (right) mice with 
conditional MST1/2 knockout for 1 year, and prostate tissue were analyzed 




















 DISCUSSION  
Androgen deprivation therapy initially decreases the volume of both primary and 
metastatic lesions, however most men experience eventual relapse. Recurring 
prostate cancer is typically ‘castration-resistant’ since removal of testicular 
androgen by chemical or surgical castration does not affect tumor growth or 
metastasis. Ultimately, the vast majority of CRPC is lethal. Thus, there is an 
urgent need to identify drug targets, and develop new therapeutic strategies to 
treat CRPC. Although the underlying mechanisms of castration resistance are 
not fully understood, both androgen receptor-dependent and –independent 
signaling pathways are known to be involved (67). Androgen receptor 
overexpression, activation and androgen secretion are the major contributors to 
androgen receptor-dependent CRPC (67-69). For example, androgen receptor 
selectively upregulates M-phase cell-cycle genes to promote CRPC (70). 
Interestingly, a recent study found that a gain-of-function mutation in 
dihydrotestosterone (the most potent androgen) synthesis partially accounts for 
castration resistance (71). However, some other studies have challenged the 
androgen receptor-dependent mechanism, as castration induces many kinases 
activation (72) and increases the expression of anti-apoptotic genes independent 
of the androgen receptor (73). Furthermore, prostate cancer stem cells have 
been proposed to be the origin of prostate cancer progression and they may not 
express androgen receptor (74). Our current study implicates YAP as a potent 
regulator for CRPC in vitro and in vivo (Figs. 2.3-9) and in clinical samples (Figs. 
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2.1,2), thus identifying YAP as a potential alternative regulator/pathway for the 
acquisition of castration resistance of prostate tumor cells. 
 
Hippo-YAP signaling is often deregulated in cancer and is a potential target for 
cancer therapy (37, 75, 76). Among the components, the YAP/TEAD complex 
represents the most attractive target for several reasons. First, TEAD 
transcription factors are required for YAP’s oncogenic activity both in cell culture 
and in vivo (77, 78). Second, TEAD is largely dispensable during normal tissue 
growth in the mouse liver (78) and in Drosophila (64) (i.e., TEAD becomes critical 
only when YAP is hyperactivated/overexpressed). Thus, there is a strong 
rationale for developing YAP-TEAD complex-disrupting agents as anti-cancer 
therapeutics against YAP-driven oncogenesis. Indeed, Liu-Chittenden et al. 
screened a small molecule library (consisting of 3,300 FDA-approved drugs) for 
agents that inhibit YAP/TEAD activity in a cell-based assay (78). Verteporfin was 
identified as an compound effective at preventing hepatic tumorigenesis driven 
by YAP overexpression (78) and the growth of xenograft tumors in 
immunodeficient mice (56, 57). Thus, verteporfin is an effective pharmacologic 
approach to inhibit YAP signaling, and these studies strongly support the 
feasibility of targeting YAP in human cancer in which Hippo-YAP is deregulated. 
Importantly, the current study showed that depletion of YAP could cause 
castration-resistant prostate cancer cells to stop growing and become androgen-
sensitive (Figs. 2.6,10,11,13). Therefore, inhibiting YAP (e.g. by verteporfin) 
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combined with hormonal therapy is a potential novel therapeutic strategy for 
prostate cancer patients with CRPC (Fig. 2.15). 
 
Previous studies, including ours, demonstrated that YAP is overexpressed or 
hyperactivated in prostate tumor samples (24, 32). Furthermore, Lats2 
expression is significantly lower in metastatic prostate tissues when compared to 
normal prostate samples (79). Interestingly, Lats2 and Mst1 have been shown to 
be associated with androgen receptor and regulate its activity (80, 81). These 
reports suggest that the Hippo-YAP pathway plays a role in the pathogenesis of 
prostate cancer. This study adds further evidence showing that the Hippo effector 
YAP regulates cell motility, invasion and castration-resistant growth of prostate 
cancer cells. Together, these studies demonstrated the biological significance of 
the Hippo-YAP signaling in prostate cancer. There are several questions that 
need to be addressed. How is YAP upregulated in castration-resistant prostate 
cancer cells? Our observations suggest that the upregulation of YAP is androgen 
receptor-independent and methylation is dispensable for YAP transcription in 
LNCaP and C4-2 cells (L.Z. and J.D., unpublished observations). Large scale 
studies failed to identify YAP amplification and mutation in CRPC. Therefore, 
future studies are needed to address the underlying mechanisms of YAP 
upregulation in CRPC. Furthermore, how is Hippo-YAP deregulated and what are 
the clinical outcomes? Answers and understanding from these questions may 
provide additional insights into the pathogenesis of prostate cancer. 
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Genetically engineered mouse alleles of the most Hippo components are 
available and these animal models provided compelling evidence showing the 
importance of Hippo-YAP signaling in human malignancies (18-20, 23-27, 82, 
83).  However, no single such model has been developed in the prostate. Our 
transgenic mouse studies showed that activated YAP or specific deletion of 
MST1/2 promotes mouse prostate cell proliferation at early age but is not 
sufficient to promote tumorigenesis in the mouse prostate. It is possible that only 
YAP activation or loss of MST1/2 is not sufficient to induce prostate 
tumorigenesis, and combination of additional alleles is necessary to induce 
prostate cancer. Since PTEN is an important tumor suppressor in prostate 
cancer, and specific deletion of PTEN in prostate leads to metastatic prostate 
cancer and castration resistance (84, 85), we are currently trying to combine the 
PTEN alleles with the Hippo (loss-of-function)-YAP (gain-of-function) signaling. A 
recent report showed that Mst1/2 deletion or YAP activation could downregulate 
PTEN, suggesting a potential link between Hippo-YAP pathway and PTEN 
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